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Abstract 
For 30 years, the tumor suppressor p53 has been a subject of intense research in 
nearly every discipline of scientific inquiry. While numerous surprising roles for p53 in 
health and disease are uncovered each year, the central role of its activation in preventing 
neoplastic transformation has been and will remain at the forefront of p53 research as 
investigators work to address an unexpectedly complex question - precisely how does 
p53 integrate upstream stress signals to coordinate activation of its target genes in 
response to stress? 
One manner in which to address this question is at the level of transcription 
initiation - after upstream signals converge on p53 and produce a number of pools of 
post-transcriptionally modified p53, how exactly are specific target promoters activated 
in such a sensitive, context-specific manner? The work presented herein aims to address 
the role of histone acetylation at the p21 promoter - a critical mediator of G liS arrest -
by the P/CAF acetyltransferase in response to a variety of p53-activating stresses. We 
show that depletion of P/CAF strongly inhibits p21 expression in response to a variety of 
stresses, despite normal stabilization of p53 and recruitment to target promoters. This 
defect in p21 expression correlates closely with abrogation of stress-induced cell-cycle 
arrest. Strikingly, a p53 allele lacking putative P/CAF acetylation sites was still able to 
direct p21 expression, which was still dependent upon P/CAF. We show further that 
histone acetylation at H3K14 at the p21 promoter following stress is dependent upon 
P/CAF. Rescue of p21 expression with wild-type P/CAF or a ~HAT point mutant 
Xll 
indicates that P/CAF requires an intact HAT domain, suggesting that histone acetylation 
at H3K14 is catalyzed by P/CAF HAT activity, not the molecular bridging of a 
heterologous HAT by P/CAF. Furthermore, RNA polymerase II (RNAP II) was present at 
the p21 proximal promoter under all basal and stress conditions, but elongation of RNAP 
II after stress required the presence ofP/CAF. These data indicate that H3K14 acetylation 
by P/CAF closely correlates with the activation status of the p21 promoter, and may be 
necessary for activation of a larger subset of p53-responsive promoters. 
In addition to its critical role in p21 expression, we noted that p53 stabilization 
and cell-cycle arrest in response to p14ARF, but not other p53-stabilizing stresses, were 
also dependent on P/CAF. Cell-cycle arrest induced by p16INK4A was intact after P/CAF 
ablation, indicating a role for P/CAF in cell-cycle arrest specific to p14ARF-p53 
signaling. Basal MDM2leveis were unaffected by P/CAF knockdown, as were p53-
MDM2 and ARF-MDM2 complexes. A preliminary analysis of MDM210calization was 
inconclusive, due to vastly different quantities of MDM2 in different conditions making 
analysis of subcellular localization difficult; however, the role of P/CAF in the 
relocalization of MDM2 to the nucleolus by p14ARF could potentially explain the defect 
in p53 stabilization, and should be explored further. 
These observations, underscored by recent reports that P/CAF undergoes loss of 
heterozygosity in several tumor types, suggest that P/CAF plays a critical role in p53-
mediated cell-cycle arrest through multiple, independent mechanisms. Further study 
should clarify whether P/CAF is lost in tumors maintaining wild-type p53, and whether 
its reintroduction into these tumors confers any potential therapeutic benefit. 
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Chapter I 
Introduction 
Principles of Tumorigenesis 
 Human cancer is a class of devastating, genetically heterogeneous diseases which, 
unlike many illnesses, spares no demographic; people of all social, economic, and ethnic 
backgrounds are afflicted. At its core, cancer is a disease characterized by unrestrained 
proliferation of a group of cells in the body. Cancer can arise in nearly any tissue type in 
the body and, through its ability to interfere with normal tissue function, can wreak havoc 
on normal human physiology; in 2008 alone, about 7.6 million deaths were caused by 
cancer – 13% of all worldwide deaths (Jemal et al., 2011). Death caused worldwide by 
malignancies is currently overshadowed only by cardiovascular and infectious disease 
(Jemal et al., 2011). 
 Cancers arise from a complex interaction of a multitude of genetic and 
environmental factors. Many well-documented occupational and recreational hazards 
exist, the most publicized in the developing world being asbestos and cigarette smoke 
exposure, respectively. Many cancer-causing infectious diseases also exist which promote 
cancer directly through encoded oncoproteins, or indirectly by creating an environment 
suitable for oncogenic mutations to arise. While many causative genetic links to cancer 
exist, even the most well-studied hereditary mutations usually account for not more than 
a fraction of total occurrences; in the absence of aggressive screening, mutation of the 
APC tumor suppressor results in highly penetrant colon cancer still accounting for only 
approximately 20-30% of cases (Rustgi, 1993). Similarly, mutations in the highly 
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publicized breast cancer-associated genes BRCA1 and BRCA2 account for an estimated 
3-5% of breast cancers (Brody and Biesecker, 1998), supporting the idea that cancer is a 
family of complex, multifactorial diseases. 
 Incidence of most cancers accelerates sharply with age (Rustgi, 1993) – an 
observation consistent with a stochastic, multi-step process in which cumulative changes 
take place over time to yield a malignancy (Weinberg, 1998). Although there is 
widespread variability in the latency of onset of various cancers, evidence suggests that 
four to six rate-limiting (Armitage and Doll, 1957; Fearon and Vogelstein, 1990) events 
must occur in a single cell lineage; this explains in part why inherited cancer-associated 
genetic mutations result in disease with highly variable penetrance (Hanahan and 
Weinberg, 2000). These four to six rate-limiting steps translate to the perturbation of a 
corresponding number of specific cellular functions. 
As mentioned above, unchecked replication of a population of cells is a necessary 
characteristic of all cancerous growths; however, this trait alone is insufficient for a tumor 
to be classified as cancerous; in addition to unrestricted growth potential, tumors must 
acquire several additional capabilities to become malignant and, in most cases, to 
significantly interfere with normal physiological functions. In addition, normal cells can 
also acquire traits such as genomic instability which increase the likelihood of subsequent 
tumorigenic events occurring. While the temporal order of acquisition of these additional 
required characteristics is still under intense investigation (and, given the broad 
heterogeneity of tissue types and nucleating genetic or environmental events, highly 
complex), broad agreement exists regarding the changes required to give rise to a 
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malignant phenotype. Broadly, these properties work together to enhance the survival of 
tumor cells through a variety of mechanisms. 
 Metazoans have evolved a complex, highly-regulated system of checkpoints to 
ensure fidelity of DNA replication, controlled proliferation, and proper cell identity. 
Malignant tumors represent a rare evasion of these control mechanisms, which include 
intrinsic limitation of proliferation through telomere attrition; resistance to intrinsic and 
extrinsic growth-suppressive or apoptotic stimuli; sustained growth signaling; and the 
characteristics that underly a true malignant phenotype – the generation and maintenance 
of new vasculature, and the activation of signaling pathways which allow for invasion of 
neighboring tissue and metastasis. These acquired traits of cancers are referred to as the 
'hallmarks' of cancer, but ongoing research continues to uncover additional acquired traits 
of cancers (Hanahan and Weinberg, 2011).  
 In addition to these well-supported hallmarks of cancer, genomic instability also 
contributes to cancer onset by shortening tumor latency. Genomic instability can be 
broadly defined as an increased tendency of the genome of a cell or clonal population to 
acquire mutations during each DNA replication cycle. Ongoing debate still rages over the 
impact of genomic instability in the onset of cancer; while some groups argue that 
genomic instability is necessary and selected for early in tumorigenesis (Loeb, 1991), 
other evidence suggests that an increased rate of cell proliferation is sufficient to allow 
the accumulation of deleterious mutations (Tomlinson and Bodmer, 1999). There are 
indeed several examples of diseases which promote rapid and sustained cell proliferation 
and are associated with increased cancer risk, despite having no direct impact on genomic 
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stability; in the liver, hepatocellular carcinoma is a common complication of cirrhosis 
brought on by alcoholism, hepatitis B, or hepatitis C, wherein the liver is under constant 
pressure to replace large populations of dead or dying hepatocytes. It is likely that both 
the rate of cell proliferation and the stability of the genome independently contribute to 
cancer risk, and therefore that intrinsic mechanisms impacting these variables, in addition 
to the aforementioned hallmarks of cancer, are also important risk determinants. The 
study of cancer biology is in essence the study of the genetic, epigenetic, and 
environmental factors that modulate these processes. 
 The genes and gene products acted upon by these influences whose alteration 
impacts cancer risks are generally classified as tumor suppressors, those genes whose loss 
of function or expression increase cancer risks through perturbation of normal function; 
or oncogenes, those genes which increase cancer risk through gain of function or 
increased expression. Both tumor suppressors and oncogenes function in a multitude of 
cellular pathways not easily categorized but that, when perturbed, can confer a selective 
advantage to the affected cell. 
 
p53: Oncogene or Tumor Suppressor? 
 For many years, a great deal of research was focused on oncogenic viruses and the 
methods by which these viruses hijack normal cellular processes to promote cancer. It 
quickly became clear that many viruses promote cancer through the expression of 
oncogenes encoded by their genomes which closely resembled host protooncogenes; 
these genes were found to be ‘hijacked’ from the host genome, as they often conferred a 
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selective advantage to the viral particles (Stehelin et al., 1976). Despite this discovery,  
the viral oncoproteins often bore little resemblance to cellular oncogenes, raising the 
question of how these proteins carry out their oncogenic functions (Stehelin et al., 1976). 
One such transforming protein encoded by simian-virus 40 (SV40), known as large-T 
antigen, was soon found to interact strongly with a host-encoded 53kD protein (Lane and 
Crawford, 1979). 
 
Initial Characterization as a Tumor Antigen 
 At the time p53 was identified as a binding partner of Large-T, cellular interactors 
of viral oncogenes were themselves bearers of oncogenic activity, and p53 was believed 
to be no exception. Further evidence continued to make the case for p53 as a oncogene or 
‘tumor-antigen’; in normal cells, p53 was present at low or undetectable levels, while 
transformed cells exhibited excessively high levels of p53 (Rotter et al., 1980). This trend 
held true in a variety of experimental settings, continuing to lend support to the idea that 
high p53 levels correlated with the presence of viral oncogenes - causative agents of 
cellular transformation. 
 After evidence continued to mount in support of the role of p53 as an oncogene, 
several groups undertook the task of cloning the p53 cDNA to more thoroughly study this 
tumor-associated protein’s properties. Several labs generated mouse and human cDNAs 
from transformed cells with high levels of p53, which facilitated easier cloning (Harlow 
et al., 1985; Oren and Levine, 1983; Wolf et al., 1985). The cDNA product was used in 
classical cooperation assays, in which two factors are introduced into cultured cells and 
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assayed for their ability to yield a transformed phenotype wherein cells exhibit 
tumorigenic properties of contact-independent growth, lack of contact inhibition, and the 
ability to form tumors in nude mice. As many expected and among several other lines of 
supportive evidence, the p53 cDNA cooperated with Ras to transform cultured cells 
(Eliyahu et al., 1984; Parada et al., 1984). It seemed unquestionable that this 53kD 
binding partner of SV40 Large-T was itself contributing to tumorigenesis. 
 
Wild-type p53 as a Tumor Suppressor 
 In spite of the mountain of evidence characterizing p53 as an oncogene, lines of 
evidence began to emerge that questioned the simplicity of this conclusion. As more labs 
cloned p53 from different sources, it became clear that not all p53 clones exhibited 
transforming activity and, further, that p53 was inactivated in mouse cells transformed by 
several oncogenic viruses (David et al., 1988; Wolf and Rotter, 1984). Further 
investigation through direct sequence analysis indicated that the first clones isolated and 
analyzed exhibited sequence variations, raising the possibility that p53 isolated from 
these tumor cells was in fact mutated (Levine and Oren, 2009). When p53 was finally 
isolated from normal murine cells, this was shown unequivocally to be the case (Finlay et 
al., 1988). Characterization of the wild-type p53 protein then began, starting with the 
analysis of  p53 loci in various tumors. Loss of heterozygosity, a hallmark of tumor 
suppressors, was found to occur in colorectal tumors through mutation or allelic loss 
(Baker et al., 1989). Additionally, in stark contrast to the potent transforming activity of 
early p53 clones with activated Ras, wild-type p53 suppressed the transforming activity 
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of known cooperating oncogenes (Eliyahu et al., 1989). Finally cementing the status of 
wild-type p53 as a tumor suppressor were the subsequent observations that Li-Fraumeni 
syndrome, characterized by early-onset cancer, is caused by p53 mutations (Malkin et al., 
1990), and that p53-knockout mice exhibit high susceptibility to tumors (Donehower et 
al., 1992). With p53 now defined as a classical tumor suppressor, attention would 
immediately turn to how these effects are exerted. 
  
p53 is a Sequence-specific Transcription Factor 
 In the many years since the final designation of p53 as a tumor suppressor, 
numerous cellular activities have been described for p53. Broadly, p53 serves to integrate 
various upstream stress sensors and responses with an appropriate cellular outcome. The 
first major functions to be attributed to p53 were potent DNA-binding (Kern et al., 1991) 
and transcriptional activation activities (Raycroft et al., 1990). Strikingly, these activities 
were absent in most of the tumor-derived p53 mutants, strongly suggesting that these 
activities contribute significantly to p53-mediated tumor suppression.  
Tumor suppression by p53 relies primarily upon its ability to transcriptionally 
activate target genes. About 50% of all cancers express mutant p53, and nearly all of 
these p53 mutants are now known to harbor missense mutations in the DNA-binding 
domain, rendering it incapable of either positively or negatively regulating transcription 
through DNA binding. Mouse knock-in models further support the role of p53 
transcriptional activities in tumor suppression, as do several correlative studies of Li-
Fraumeni patients, wherein transcriptional capabilities of inherited p53 mutants 
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correlated with clinical manifestation of resulting tumors (Monti et al., 2007). 
The importance of p53 transcriptional activity in tumor suppression is 
unquestionable, and will be described in further detail below. However, it is important to 
note that, although most attention has focused on p53 as a transcriptional activator, p53 
also performs several important transcription-independent functions, including but not 
limited to transcriptional repression (Ho and Benchimol, 2003), fine-tuning DNA damage 
repair by homologous recombination (Bertrand et al., 2004), and involvement in 
mitochondrial outer membrane permeabilization critical to induction of apoptosis (Vaseva 
and Moll, 2009). 
 
Control of p53 Activity: the MDM2-p53 Feedback Loop 
 The ability of a single protein to eliminate a cell from the replicative pool 
necessitates that its activities be kept checked under basal conditions. In contrast to the 
massive overexpression of mutant p53 in many tumors, wild-type p53 is kept at very low 
basal levels in most unstressed cells. This is achieved through the activity of the E3 
ubiquitin ligase MDM2. E3 ubiquitin ligases exert their activities through the covalent 
linkage of a ubiquitin molecule to a substrate which, depending upon the number of 
ubiquitins and the specific lysine to which subsequent ubiquitins are linked, signals one 
of many outcomes for the substrate. The transfer of a ubiquitin molecule to a substrate 
involves the concerted activity of at least three enzymes: the ubiquitin-activating enzyme 
E1, which is conjugated to ubiquitin via a high-energy thioester bond; a ubiquitin-
conjugating, or E2, enzyme, to which the E1-bound ubiquitin is transferred; and an E3 
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which, depending on its class, directly or indirectly catalyzes the transfer of the E2-bound 
ubiquitin to a substrate lysine (Pickart, 2001). Generally, ubiquitin molecules linked by 
K48 to G76 of a subsequent ubiquitin molecule tend to direct the substrate for 
proteasomal degradation when a sufficient chain length, usually four, is reached. In 
contrast, K63 to G76 linked ubiquitin chains signal various non-proteasomal fates for 
their substrates (Pickart et al., 1999; Spence et al., 2000). 
 In the case of p53, MDM2 is a RING finger E3 that is well known to direct the 
addition of K48-linked ubiquitin to several C-terminal lysines of p53 and to occlude the 
p53 transactivation domain (Haupt et al., 1997; Honda et al., 1997; Momand et al., 1992). 
In conjunction with E4 (ubiquitin-chain extending) 0.ubiquitin ligase activities of the 
p300 and CBP acetyltransferases, K48 ubiquitin chains are extended on p53, targeting it 
for degradation by the proteasome (Grossman et al., 2003a; Shi et al., 2009b). Validating 
the importance of MDM2 in keeping p53 in check was the observation that embryonic 
lethality in MDM2-null mice can be completely rescued by concomitant deletion of p53 
(Jones et al., 1995; Luna et al., 1995), implying that a primary function of MDM2 is to 
control p53 activity under non-stress conditions. Furthermore, MDM2 is overexpressed in 
many sarcomas which, in many cases, is mutually exclusive with p53 mutation (Florenes 
et al., 1994), suggesting that MDM2 overexpression can often render p53 signaling 
inactive (although many p53-independent activities of MDM2 likely contribute to 
tumorigenesis as well). 
 MDM2 antagonizes p53 activity primarily by promoting its ubiquitination and, 
independently, attenuating p53 transcriptional activity through direct interaction with 
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p53. Both crystalization and biochemical structure/function analysis of the p53-MDM2 
complex have yielded insights into the nature of this interaction, which involves an N-
terminal hydrophobic cleft of MDM2 spanning aa 25-109 interacting with a small 
hydrophobic portion of the p53 transactivation domain spanning aa 19-26 (Chen et al., 
1993; Kussie et al., 1996). Additionally, the p53 C-terminal tetramerization domain is 
also necessary for efficient MDM2 binding (Maki, 1999). This interaction with the p53 
N-terminus serves to occlude the p53 transactivation domain, thereby rendering it 
transcriptionally inactive while in complex with MDM2 (Kussie et al., 1996). 
Phosphorylation events in the p53 N-terminus, which will be discussed in more detail 
below, serve to weaken the p53-MDM2 interaction  through reduction of hydrophobicity 
of N-terminal residues (Schon et al., 2002), thereby antagonizing the negative regulatory 
functions of MDM2 toward p53. While the outcome of p53-directed ubiquitination by 
MDM2 is highly context dependent, it is likely that ubiquitination negatively regulates 
p53 activity through affecting p53 localization (Stommel et al., 1999), transcriptional 
activity (Brooks and Gu, 2006), competing against other post-translational modifications, 
or directly promoting degradation by facilitating the delivery of p53 to the 26S 
proteasome (Brignone et al., 2004; Kulikov et al., 2010).  
Further work has suggested a complex stoichiometry of the interaction – MDM2 
oligomerization appears necessary to activate its E3 activity, and this oligomerization 
event is likely dependent on additional factors including the close MDM2 homolog 
MDM4 (Linke et al., 2008). The spatial organization of the MDM2 oligomer is a tail-to-
RING domain interaction between neighboring MDM2 molecules, which facilitates the 
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activation of the E3 activity of the RING domain and substrate ubiquitination. This 
change in activity may be facilitated through augmentation of MDM2-E2 binding 
(Poyurovsky et al., 2007).  
 In addition to the complex biochemical interplay between p53 and MDM2, there 
exists another level of genetic complexity to the interaction: MDM2, the primary 
negative regulator of p53 activity, is itself a high-affinity p53 target gene (Barak and 
Oren, 1992; Otto and Deppert, 1993; Wu et al., 1993). This interaction generates a 
negative feedback loop whereby stress-induced activation of p53 culminates in induction 
of MDM2, which then serves to dampen p53 activity. It is the interruption of this 
feedback loop by the inability of mutant p53 to transactivate MDM2 that results in its 
overexpression in many cancers. The physiological significance of this feedback loop is 
evidenced by the fact that in many cancers retaining wild-type p53, MDM2 is 
overexpressed, suggesting that either p53 mutation or MDM2 overexpression achieve an 
outcome of hampering p53 activation (Daujat et al., 2001). Precisely how the MDM2-p53 
interaction is regulated by upstream p53-activating signals will be described in more 
detail below. 
 
Upstream Activators of the p53 Program 
 p53 is a potent sensor of an ever-increasing range of cellular stresses; DNA 
lesions from a broad spectrum of environmental or chemical sources, hyperproliferation, 
improper timing of activation of many protooncogenes, hypoxic conditions, and telomere 
erosion are just a few of the stresses that lead to p53 stabilization and activation. In the 
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past few years alone, p53 has been linked to the tanning response (Cui et al., 2007), 
defined as an antagonist of induced pluripotent stem-cell (iPS cell) generation (Banito et 
al., 2009; Marion et al., 2009), and even as a regulator of embryonic implantation (Hu et 
al., 2007). Still, the most well-studied and, arguably, relevant functions to tumor initation 
and progression, are the p53-dependent responses to DNA-damage and oncogene 
activation (Figure 1.1). 
 
DNA-damage 
 Numerous chemical and environmental, and even normal metabolic causes of 
DNA damage exist in nature. Oxidative respiration causes the generation of reactive 
oxygen species (ROS), which cause base modifications in DNA that have various, usually 
detrimental effects. Ultraviolet radiation also contributes to the development of some 
tumors (Brash et al., 1991) through the generation of pyrimidine dimers which commonly 
result in base substitution. These lesions can result in point mutations and chromosomal 
aberrations that can often result in oncogene expression or tumor suppressor inactivation, 
underscoring the need for a rapid, robust response to these threats to genomic integrity. 
The potent G1 arrest mediated by p53 in response to various types of DNA damage is 
mediated primarily by the ATM and ATR kinases, with Akt and the DNA-dependent 
protein kinase (DNA-PK) being additionally necessary for p53 accumulation in response 
to sources of high frequency gamma irradiation (Boehme et al., 2008).  
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Figure 1.1: The p53 Tumor Suppression Pathway. An overview of the p53 pathway 
including p53-activating stresses such as DNA damage, oncogene activation, telomere 
attrition, or hypoxia (top row), the transducers of these stress signals to p53 (second row), 
and the physiologic outcomes directed by activated p53 (grey ovals), which can include a 
transient or permanent cell-cycle arrest, or apoptosis. 
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Adapted from Riley et al 2008, Nature Reviews Molecular and Cell Biology  
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 ATM/ATR and DNA-PK sit at the top of the double-strand break response 
pathway. ATM is recruited as a dimer to double-strand breaks (DSBs) by the 
Mre11/Rad50/Nbs1 (MRN) complex. Once recruited to DSBs, ATM undergoes an 
autophosphorylation which results in the dissociation of the ATM dimer, yielding ATM 
monomers with kinase activity (Bakkenist and Kastan, 2003) which serve to 
phosphorylate a host of substrates in the DNA-damage response. ATR seems to function 
analogously to ATM, but responds to a different subset of DNA lesions such as single-
strand breaks generated by UVB radiation (Zou and Elledge, 2003) and, in contrast to 
ATM, appears to be necessary for normal cell-cycle progression (Brown and Baltimore, 
2003). DNA-PK is activated directly through its autophosphorylation in the presence of 
DSBs (Smith and Jackson, 1999). 
In response to the activation of any combination of these kinases, p53 is 
phosphorylated at several serine residues, most notably serine 15. In addition, DNA-PK 
also phosphorylates p53 at serine 37 and 46 (Hill et al., 2008; Komiyama et al., 2004; 
Leesmiller et al., 1992), while ATM and ATR also target serine 20 for phosphorylation 
indirectly through the activation of the checkpoint kinases Chk1 and Chk2 (Donehower et 
al., 1992). Phosphorylation of these residues, located in the N-terminal transactivation 
domain of p53, may serve to disrupt the p53-MDM2 interaction, although more work is 
necessary to rigorously test this hypothesis. In addition, ATM phosphorylates the MDM2 
C-terminus, stimulating its autoubiquitination, thereby targeting it for proteasomal 
destruction (Stommel and Wahl, 2005) and allowing stabilization of p53 through a 
reduced rate of proteasome-dependent turnover. 
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Oncogenic Stress: p14ARF 
 The threat of extensive DNA-damage to the health of an organism is 
unquestionable; however, to our understanding the broadest purpose of tumor suppression 
is to prevent the improper activation of proto-oncogenes which could constitute a threat 
to the organism as a whole. While DNA-damage alone can, and often does, result in the 
activation of oncogenes through amplification or mutational events, other DNA-damage 
independent paths exist to oncogene activation. This necessitates the need for a robust 
response to these events, even in the absence of genetic lesions. In vertebrates, this 
response is largely controlled by the gene products of the INK4A locus. 
 The INK4A locus, located at chromosome 9p21 in humans, encodes two potent 
tumor suppressors, p16INK4A and ARF, encoded in alternative reading frames, which are 
therefore structurally unrelated. ARF, aptly named the alternative reading frame of the 
locus, is the product of a promoter and first exon (exon 1β) that is unique from 
p16INK4A, but is then spliced into an alternate reading frame of common exons 2 and 3 
of p16INK4A (Quelle et al., 1995). Interestingly, although the locus is conserved 
throughout vertebrate evolution, only the first 25 amino acids of ARF, corresponding to 
exon 1β, are conserved. This suggests that evolutionary relevant functions of ARF are 
provided by the first 25 amino acids (Kim et al., 2003), although the identification of a 
nucleolar localization signal (NoLS) in exon 2 which regulates SUMOylation of MDM2 
may challenge this assumption (Xirodimas et al., 2002). 
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Figure 1.2: Overview of the ARF Signaling pathway. ARF is expressed in response to 
several oncogenic stimuli, and activates p53 by directing MDM2 degradation and 
nucleolar relocalization. Depending upon environmental context, p53 directs a pro-
apoptotic or cell-cycle arrest program in response to ARF 
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Figure 1.2: Overview of the ARF Signaling pathway 
 
 
 
 
 
 
 
 
 
 
 
Adapted from Sherr, CJ 2006, Nature Reviews Cancer 
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p16INK4A had been previously characterized as an antagonist of CDK4/6 activity 
through inhibition of cyclin-D binding, leading to Retinoblastoma (Rb) 
hypophosphorylation and inhibition of cell-cycle progression (Serrano et al., 1993). 
Furthermore, before the discovery of ARF, deletion of the locus had already been 
observed at a high rate in a variety of malignancies, suggesting a tumor suppressive 
activity at 9p21 (Sharpless and DePinho, 1999). ARF was soon characterized and also 
discovered to harbor a potent cell-cycle inhibitory activity (Quelle et al., 1995) at both 
G1/S and G2/M phases, as evidenced by the upregulation of p21 and 14-3-3σ in response 
to forced ARF expression (Hemmati et al., 2008). These properties appeared to confer 
tumor suppressive capacity, as mice engineered to lack exon 1β (but retain p16INK4A 
expression) were shown to be highly tumor prone, suggesting that mouse ARF, not 
p16INK4A, may be the relevant tumor suppressor at 9p21 (Kamijo et al., 1997). 
While mice lacking ARF are given to spontaneous tumor formation, evidence for 
the role of human ARF versus p16INK4A in tumor suppression is less well-defined. 
Complicating these studies in part is the architecture of the locus itself, the entirety of 
which is often lost in most cancers. When mutations in the INK4A locus do occur in 
human cancer, they often occur with concomitant loss of function of both ARF and 
p16INK4A, making assessment of the relative contribution of each to the malignancy 
difficult. However, most hypermethylation or deletion events that are selective for one of 
the two gene products target p16INK4A in humans, whereas selective ARF inactivation is 
much (about a factor of 20) more rare (Kim and Sharpless, 2006; Sharpless and Chin, 
2003). Still, a few lines of research suggest a role for selective loss of ARF in human 
20 
 
tumor development. First, a group of familial melanoma and astrocytoma kindreds 
exhibit exon 1β mutations that, as expected, do not affect p16INK4A function (Rizos et 
al., 2001). Additionally, inactivation of ARF by promoter hypermethylation in the 
absence of p16INK4A hypermethylation has been shown to occur in colon cancers 
(Esteller et al., 2000; Sato et al., 2002) and Merkel cell carcinoma (Lassacher et al., 
2008). Additionally, immortalization of cultured mammary epithelial cells (MECs) by 
high-risk HPV E6 is closely associated with loss of ARF signaling. 
Differences in activation of the gene products between mice and humans are more 
pronounced. As each factor encoded by INK4A is a potent cell-cycle inhibitor, activation 
of each must be tightly regulated to allow cell-cycle progression under normal conditions. 
This is achieved primarily through the regulation of expression of each or both factor(s) 
by upstream oncogenic signals (although, importantly, both products have been noted as 
targets of MDM2-independent polyubiquitination and proteasomal degradation, 
suggesting possible post-transcriptional regulation of each) (Ben-Saadon et al., 2004; 
Kuo et al., 2004). In mice, expression is largely coregulated (Krishnamurthty et al., 
2004), with both senescence or activated Ras resulting in increases of both ARF and 
p16INK4A expression levels. In humans, however, p16INK4A alone appears to respond 
to replicative senescence and activated Ras (Huot et al., 2002). 
Further analysis of p14ARF, however, has proven that its cell-cycle regulatory 
properties are more complex. While normal replicative senescence does not appear to 
activate ARF in humans, oncogene-induced senescence appears to be regulated by ARF 
in certain contexts (Sekaric et al., 2007a). Additionally, E2F1 and Ras were observed to 
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synergistically activate p14ARF in primary fibroblasts (Berkovich and Ginsberg, 2003). 
One surprising study failed to detect p14ARF in passaged primary fibroblasts, yet 
siRNA-mediated knockdown of p14ARF increased the growth rate of these cells in a 
p53-dependent manner. Knockdown of p16INK4A in the same experimental setting 
provided a growth advantage only with concomitant loss of p14ARF, suggesting that 
combined loss of the entire locus contributes to an enhanced growth rate of human 
fibroblasts (Voorhoeve and Agami, 2003). While marked differences exist between ARF 
regulation in mice and humans, much more comprehensive analyses are required to 
discern precisely how, and under what conditions, p14ARF is activated. 
 Once expressed through the action of the oncogenic signaling pathways described 
above, p14ARF exerts a subset of its activities through p53 stabilization and p21 
induction in a complex and still incompletely understood manner (Figure 1.2). Notably, 
p14ARF has been shown to possess p53-independent cell-cycle inhibitory and apoptotic 
functions in part through the CtBP family of transcriptional repressors (Kovi et al., 2010; 
Paliwal et al., 2006), but these activities will not be discussed in detail. The process likely 
begins with p14ARF forming a ternary complex with MDM2 and p53, inhibiting the E3 
ligase activity of MDM2 toward p53 (Xirodimas et al., 2001), and effecting the rapid 
proteasomal degradation of MDM2. This p53-ARF interaction requires the presence of 
MDM2 and the N-terminal exon 1β-encoded amino acids of ARF, suggesting that the 
ARF N-terminus interacts with MDM2, which bridges the ARF-p53 interaction (Zhang et 
al., 1998). ARF interaction with MDM2 appears necessary for the stabilization of p53, 
and appears to occur through multiple domains of MDM2 (Clark et al., 2002).  
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 An additional complexity of the MDM2-ARF axis arises from the many reports 
that ARF is predominantly nucleolar. Furthermore, in the presence of ARF, MDM2 is also 
localized to the nucleus, suggesting that ARF may serve to either inhibit nucleolar-
cytoplasmic shuttling of the MDM2-p53 complex (Tao and Levine, 1999), or to directly 
sequester ARF-MDM2 complexes in the nucleolus (Weber et al., 1999). The authors 
noted that ARF mutants failing to reach the nucleolus but still capable of interacting with 
MDM2 were unable to activate p53, supporting the notion that nucleolar localization of 
ARF is necessary for MDM2 inhibition; however, several challenges to this hypothesis 
indicate a more complex picture. Work from the lab of Gordon Peters noted several cases 
in which non-nucleolar ARF can direct p53 stabilization despite relatively high levels of 
nucleoplasmic MDM2 (Llanos et al., 2001). Subsequent work from the same lab 
indicated that nucleolar ARF is highly stable relative to nucleoplasmic ARF, raising the 
possibility that nucleolar ARF serves as a potential reservoir for nucleoplasmic ARF, 
where it may predominantly exert its critical functions (Rodway et al., 2004). 
 Once released from MDM2-mediated ubiquitination and transcriptional inhibition 
by p14ARF, p53 is stabilized and, through mechanisms still under investigation, becomes 
active. p14ARF was recently shown to direct the acetylation of p53 in both the DNA-
binding domain at lysine 120 (Mellert et al., 2007), and the C-terminus (Sekaric et al., 
2007a). Lysine 120 is a known substrate of Tip60/hMOF-mediated acetylation, but the 
physiologic HAT responsible for ARF-induced lysine 120 acetylation has not yet been 
definitely identified. While C-terminal acetylation of p53 is known to involve the p300 
and CBP acetyltransferases (Luo et al., 2004), work from the Androphy lab has presented 
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convincing evidence that the transcriptional adaptor hAda3, a stable component of the 
P/CAF complex (Ogryzko et al., 1998), regulates ARF-induced acetylation of p53 C-
terminal lysines. Strikingly, siRNA-mediated ablation of hAda3 completely abrogated 
p53 stabilization in response to ectopic p14ARF, suggesting that acetylation may be 
necessary for p53 stabilization (Sekaric et al., 2007a). This dissertation will present 
evidence that P/CAF may indeed be the HAT responsible for acetylation of the p53 C-
terminus, and this function is critical in promoting p53 stabilization in response to 
p14ARF. 
In addition to the complex interplay between p14ARF and MDM2 in p53 
activation, one report suggests that p14ARF must also inactivate another E3 ubiquitin 
ligase – ARF-BP1/Mule – for p53 stabilization. This report indicates that this ubiquitin 
ligase, identified as an E3 ligase for the anti-apoptotic factor Mcl-1 (Zhong et al., 2005), 
also harbors E3 activity toward p53, the ARF-dependent inhibition of which is critical for 
proper p53 activation (Chen et al., 2005). The potential therapeutic importance of ARF-
BP1/Mule is also underscored by the observation that its targeted inhibition in a variety 
of cancer cells induces cell-cycle arrest or apoptosis (Chen et al., 2006). Further work 
will be necessary to more accurately define the complex biochemical network that 
coordinates the tumor suppressive activities of ARF. 
  
Coactivators of p53-dependent Transcription 
 In the context of the complex chromatin environment that houses the genome, 
eukaryotes have evolved mechanisms to tightly regulate the temporal activation of 
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transcription at many loci. Stress-induced factors which present an existential threat to 
the cell, such as many transcriptional targets of p53, make this need abundantly clear. In 
eukaryotes, one level of transcriptional control is provided a large, structurally and 
functionally heterogeneous class of proteins known as transcriptional coregulators. While 
these factors lack DNA-binding domains, they are capable of interacting with 
transcription factors to enhance or repress expression of their target genes. 
Transcriptional coactivators, which are well studied with respect to p53, broadly 
function to disrupt higher-order chromatin structure and nucleosome-DNA interactions to 
allow transcriptional initiation and elongation. These factors fall into one of two major 
groups: histone acetyltransferases (HATs) serve to facilitate transcriptional activation 
through acetylation of histone or non-histone factors, whereas ATP-dependent chromatin 
remodeling proteins of the mammalian homologs of the yeast SWI/SNF complex disrupt 
nucleosome-DNA interactions. While the SWI/SNF proteins are critical for the 
coordination of regulated transcription and should be studied in more detail with regard 
to p53-dependent transcription, the bulk of research on p53 coactivators has focused on 
the role of HATs in regulation of p53 activity. 
 
The Many HATs of p53 
 Since four simultaneous communications highlighted the role of the paralogous 
HATs p300 and CBP as p53 coactivators (Avantaggiati et al., 1997; Gu et al., 1997; Lill et 
al., 1997; Scolnick et al., 1997), numerous HATs with various activities toward p53 have 
been described. Far from playing a simple coactivator role in the activation of p53 target 
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genes by acetylating histones, several p53 HATs are now known to alter p53 activities 
through direct acetylation (Gu and Roeder, 1997; Tang et al., 2006), through novel E3 or 
E4 (ubiquitin-chain extending) ligase activities (Grossman et al., 2003a; Linares et al., 
2007; Shi et al., 2009a), or by direction of these biochemical activities toward other 
modulators of the p53 pathway (Linares et al., 2007; Shin and Janknecht, 2007; Wang et 
al., 2004). While the bulk of data in this dissertation concerns the impact of P/CAF on 
p53 stability and p21 transcription, p300/CBP and Tip60/hMOF play important roles in 
these processes (Figure 1.3) which need to be considered in the development of a 
comprehensive model for the role of HATs in p53 function.  
 
p300 and CBP 
 p300 and CBP are unquestionably the most well-studied HATs with respect to p53 
function. As mentioned above, these factors were defined as p53 coactivators, likely 
owing both to their ability to bridge interactions between transcription factors and RNA 
Polymerase II (RNAPII) (Goodman and Smolik, 2000), and through their acetylation of 
promoter histone tails. Initial characterization of p300 and CBP histone acetylation 
activity identified four lysines of the N-terminal histone 4 (H4) tail as substrates 
(Ogryzko et al., 1996). Recent in vivo analysis of p300/CBP double-knockout MEFs 
confirms this observation, as H4 acetylation at all four N-terminal lysines – K5, K8, K12, 
and K16 – was strongly attenuated at known p300/CBP-responsive genes (Kasper et al., 
2010). 
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This broad role for p300/CBP in transcriptional activation extends to p53, as 
evidenced by the requirement for p300 in directing the p53-dependent in-vitro 
transcriptional activation of a purified, chromatin-assembled p21 promoter (Espinosa and 
Emerson, 2001). Importantly, the relevant function of p300 in this study was acetylation 
of nucleosomal histones; p53 acetylation was dispensable for p21 activation, at least in 
this context, although it is possible that other non-structurally related HATs such as 
Tip60/hMOF or P/CAF/GCN5 could obviate the requirement for p300 in this 
experimental setting. Importantly, CBP recruitment to the p21 promoter following 
irradiation of U2OS cells 
correlates with increased histone acetylation (Barlev et al., 2001). 
 Complicating the simple hypothesis that p300 and CBP function as histone 
acetyltransferases for p53 are several reports indicating that p300 or CBP are either 
completely dispensable for p21 transactivation (Kasper et al., 2010), or that their HAT 
activities are not necessary for p21 transactivation (Puri et al., 1997). The latter report 
suggests that P/CAF provides the necessary HAT activity, functioning through interaction 
with p300/CBP to facilitate activation of p21. The role of CBP and p300 in p53-
dependent transactivation of the p21 promoter is likely extremely complex and context 
specific, and will require a great deal more research to fully understand. The involvement 
of P/CAF in p21 expression will be described further below. 
 A less controversial function of p300 and CBP activity in p53 function is the 
direct acetylation of p53 by p300 and CBP. p53 was identified by mass spectrometry as
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Figure 1.3: Impact of p53 acetylation by Tip60/hMOF, p300/CBP, or P/CAF on cell fate. 
Acetylation of K120 by Tip60/hMOF results in increased association of p53 with low-
affinity apoptotic promoters. K320 acetylation, possibly mediated by P/CAF, is 
associated with cell-cycle arrest. Acetylation of C-terminal lysines by p300 and CBP 
increase association with apoptotic promoters. The role of the recently described 
acetylation site at K120 remains unclear but, when mutated in combination with the other 
seven acetylation sites, abolishes p21 activation. 
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Figure 1.3: Impact of p53 acetylation by Tip60/hMOF, p300/CBP, or P/CAF on cell fate. 
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the first non-histone protein to be acetylated by a HAT. p53 is acetylated by p300/CBP at 
six C-terminal lysines surrounding the tetramerization domain(Gu and Roeder, 1997), as 
well as in the DNA-binding domain at K164(Tang et al., 2008). Subsequent studies 
suggested numerous functions for acetylation of the p53 - augmentation its DNA-binding 
capability (Luo et al., 2004), inhibition of ubiquitination of C-terminal lysines(Li et al., 
2002), facilitation of cofactor recruitment (Barlev et al., 2001). Mutation of the six C-
terminal lysines (6KR) acetylated by p300 and CBP result in attenuated expression of a 
subset of p53 targets (Feng et al., 2005), suggesting that acetylation of these residues play 
an important role in p53-dependent transcription. Strikingly, mutation of K164 and the 
Tip60 target K120 in combination with 6KR completely impair p53-regulated cell-cycle 
arrest and apoptosis, with only the p53-MDM2 feedback loop remaining intact (Tang et 
al., 2008). These observations further underscore the importance of p53 acetylation in its 
activation, and suggest that p21 expression is, in a manner yet to be completely 
elucidated, dependent upon some degree of p53 acetylation. 
 p300 and CBP have been historically known as coactivators through their 
acetylase activities, but p300/CBP have also been shown to play in important role in 
promoting p53 degradation (Grossman et al., 2003a) (Shi et al., 2009a). Early lines of 
evidence indicated that p300 is present in MDM2-p53 complexes, and that an MDM2 
mutant deficient in p300 binding is unable to degrade p53, despite retaining robust p53 
interaction, proper localization, and containing an intact RING domain (Grossman et al., 
1998). Furthermore, expression of adenovirus E1A has long been known to stabilize p53 
in a manner dependent upon p300/CBP binding (Somasundaram et al., 1997). The 
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definitive role for p300 in p53 stability was described when p300 was shown to exhibit 
intrinsic autoubiquitination activity and ubiquitin ligase activity toward p53 in vitro. 
Importantly, p300 was only able to ubiquitinate monoubiquitinated p53, designating it as 
an E4 ubiquitin ligase (Grossman et al., 2003a). Subsequent work also identified CBP as 
an E4, and validated the roles of each in p53 degradation in vivo. Interestingly, the 
authors noted that purified cytoplasmic p300 and CBP exhibited robust E4 ubiquitin 
ligase activity, while nuclear p300 and CBP lacked E4 activity. This observation could 
potentially reconcile the opposing functions of p300 and CBP in regulating p53 activity.  
Continuing research will be necessary to determine whether the negative 
regulatory activities of p300/CBP toward p53 are limited to non-stress conditions, or if 
p300/CBP-directed ubiquitination of p53 serves additional purposes; perhaps in promoter 
clearance, restoration of low p53 levels following stress, transcriptional regulation, or any 
number of other possibilities. Additionally, the positive-acting roles of p300 and CBP as 
coactivators of p53-directed transcription will require further attention – RNAi 
approaches should allow the dissection of which subset(s) of p53-responsive genes 
require the presence of p300 or CBP as a coactivator. 
 
Tip60 and hMOF 
 Tip60 and hMOF are members of the evolutionarily conserved family of 
‘Moz,Ybf2/Sas3,Sas2, and Tip60’ (MYST) histone acetyltransferases. Tip60 is involved 
in numerous cellular processes such as DNA damage, apoptosis (Ikura et al., 2000), and 
maintenance of stem cell identity (Fazzio et al., 2008). Tip60 exerts most of these 
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activities in part through acetylation of H4 at lysines 5, 8, 12, and 16, as well as a number 
of non-histone targets(Sapountzi and Cote, 2011). Little is known about hMOF, but it too 
appears to play a role in the DNA-damage response through association with ATM and 
acetylation of H4 at lysine 16 (Gupta et al., 2005; Taipale et al., 2005). Recently, Tip60 
and hMOF were both independently identified to modulate p53 activity through 
acetylation of K120 (Sykes et al., 2006; Tang et al., 2006), a highly conserved residue 
present in the DNA-binding domain. Strikingly, both reports noted that acetylation of 
K120 seemed to regulate apoptosis induction by p53, as its mutation attenuated p53 
recruitment and transcription at apoptotic promoters such as PUMA and Bax, but had no 
effect on induction of p21 and MDM2. Of note, Tip60 appeared to play a critical role in 
acetylation of H4 at the p21 promoter – while the p53 K120R mutant retained the ability 
to transactivate the p21 promoter, Tip60 knockdown strongly attenuated p21 expression 
in response to etoposide. Further analysis indicated that Tip60 was recruited to the p21 
promoter following stress, and its presence correlated with acetylation of H4. 
 
 
P/CAF and GCN5 
 P/CAF and GCN5 are members of the GCN5-related N-acetyltransferase, or 
GNAT, family of histone acetyltransferases. Both mammalian P/CAF and GCN5 C-
terminal halves bear strong sequence similarity to yeast GCN5 and contain an 
evolutionarily conserved HAT domain. Metazoan P/CAF and GCN5, however, have 
evolved a long N-terminal extension whose function was elusive until the recent report 
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that it encodes an intrinsic E3 ubiquitin ligase activity, which will be described in more 
detail below. P/CAF and GCN5 function in large multi-protein complexes – the 2MDa 
STAGA/SAGA and P/CAF complexes, which seem to share most subunits but differ in 
whether their catalytic activity is provided by P/CAF or GCN5; and the smaller ~700kD 
ATAC complex, which may share similarity to the yeast ADA complex (Nagy and Tora, 
2007). 
 The GCN5 and P/CAF complexes have a relatively broad substrate specificity for 
lysines of histone 3. In vitro and in vivo studies indicating that H3K14 is a primary 
substrate of GCN5 (Brand et al., 1999; Guelman et al., 2006) are supported by X-ray 
crystallographic data indicating that an 11-amino acid peptide of H3 centered around K14 
fits closely into a protein cleft formed by the folded structure of the GCN5 core domain 
in combination with both the N- and C-termini (Rojas et al., 1999). More limited research 
has focused on P/CAF, but broad agreement exists that N-terminal tails of histone 3 are 
primary substrates of the P/CAF complex in vitro and in vivo (Ogryzko et al., 1998).  
 The first evidence that P/CAF plays a role in p53 transactivation arose from the 
observation that transfected P/CAF enhanced transactivation of the p21 
promoter(Scolnick et al., 1997), presumed to occur through enhancement of nucleosomal 
histone acetylation. Two subsequent studies dissecting the complex series of signals that 
culminate in p53 activation suggested that, in addition to the acetylation of C-terminal 
lysines, lysine 320 is acetylated following UV or ionizing radiation. It was noted that 
P/CAF efficiently acetylated p53 lacking the C-terminal regulatory domain, while p300 
was unable to acetylate this mutant (Liu et al., 1999). Importantly, mass spectrometric 
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analysis of in vitro-acetylated p53 also confirmed this result(Sakaguchi et al., 1998), as 
did later reports indicating that overexpression of P/CAF stimulates acetylation of p53 
K320 in cells (Jin et al., 2002; Linares et al., 2007). To date, and perhaps surprisingly, 
there have been no reports of p53 acetylation by GCN5. 
 Several lines of evidence to date suggest that P/CAF and, to a lesser extent, GCN5 
play an important role in p53-directed stress responses. In addition to the first report that 
P/CAF stimulates p21 expression, mentioned above, two recent reports indicate that 
P/CAF is necessary for full expression of p21 (Di Stefano et al., 2005b; Linares et al., 
2007). In addition, despite the paucity of literature addressing GCN5 in p53 activity, one 
report from the Roeder lab suggests that the GCN5-containing STAGA complex enhances 
p53-dependent transcription, as GCN5 knockdown partially inhibits UV-induced 
activation of PUMA and p21. Furthermore, GCN5 interacts with p53 in cells and is 
recruited to active promoters with p53, correlating with acetylation of histone 3(Gamper 
and Roeder, 2008). These lines of evidence suggest that P/CAF and GCN5 function as 
coactivators in p53-dependent transcription of a subset of target genes, albeit in an 
incompletely understood manner. 
 Acetylation of p53 K320 has been presumed to be the primary manner through 
which P/CAF regulates p53. This modification regulates diverse cellular processes – 
mutation of K319-321 to arginines results in attenuated transcriptional activation of a 
p21-luciferase reporter (Liu et al., 1999). In addition, expression of a K320Q acetylation 
mimic in p53-null H1299 cells exhibits markedly different effects on p53-responsive 
promoters than expression of a wild-type or K373Q mutant. One comprehensive report 
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indicates that K320Q is not able to induce expression of most apoptotic genes, yet 
strongly activates cell-cycle arrest and anti-apoptotic promoters; in contrast, K373Q 
strongly activates many apoptotic genes such as APAF1, caspase-6, and PIG-3 while 
actively repressing expression of many pro-survival genes (Knights et al., 2006). Further 
analysis indicates that K373Q was also efficiently recruited to apoptotic promoters, 
whereas K320Q bound strongly to the p21 promoter but not apoptotic, low-affinity 
promoters. These results suggest that acetylation of K320 may prevent activation of 
several low affinity p53-responsive promoters, thereby modulating the decision between 
cell-cycle arrest and apoptosis. 
 Despite mounting evidence suggesting that K320 acetylation is a biologically 
relevant modification of p53, and that P/CAF overexpression stimulates this modification 
in vitro and in cells, the true mediator of K320 acetylation remains unclear; despite 
numerous reports of P/CAF overexpression stimulating this modification, no reports to 
date have addressed the impact of HAT depletion on K320 acetylation, leaving open the 
possibility that P/CAF is a limiting adaptor and may function through other mechanisms 
to modulate p53-dependent transcription. Many of the experiments described in this 
dissertation will address the mechanism through which P/CAF promotes p53-dependent 
p21 transcription in response to various stresses. 
 
Transcriptional Regulation by p53 
 p53 was formally identified as a transcriptional activator with sequence specificity 
in 1992 by Bert Vogelstein and colleagues. The group identified the p53 consensus 
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binding sequence as two inverted RRRCWWGYYY repeats separated by a short (0-
21bp) spacer(el-Deiry et al., 1992). Since this definition, many sequence-based 
biochemical and computational approaches have been undertaken to predict and 
functionally validate potential p53 target genes; a 2006 report utilizing a global 
chromatin-immunoprecipitation strategy identified 542 p53-binding sites, while more 
recent approaches have even implicated p53 in the direct activation of microRNAs, 
further expanding the list of p53 transcriptional targets. 
 p53 directs an appropriate cell-fate outcome in part through differential activation 
of target genes in a cell-type and stress-specific manner (Espinosa, 2008), implying that 
the p53 transcriptional program is tightly regulated. In general, p53 is described as 
directing an outcome of transient cell-cycle arrest or apoptosis, with variations such as 
senescence, a permanent G0 arrest, often considered separate outcomes. Early 
experiments dissecting the transcriptional p53 response indicated that kinetics of 
induction of p53 differed, with cell-cycle arrest genes broadly displaying fast, often 
transient expression; while apoptotic genes generally display delayed but sustained 
expression kinetics (Zhao et al., 2000). Over the years, a variety of hypotheses have been 
proposed to explain the specificity of p53 in target gene regulation. 
It was initially believed that the activation status of target promoters correlated 
with the presence of p53 at the p53 REs of those promoters. This hypothesis met with 
some support owing to differential binding affinity of p53 REs in different subsets of 
p53-regulated genes; however, mounting evidence suggests that promoter occupancy by 
p53 of p21, a target gene responsible for inducing cell-cycle arrest, reflects the total 
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cellular concentration of p53 irrespective of the transcriptional state of the p21 promoter 
(Espinosa et al., 2003). Specifically, stresses that resulted in p53 stabilization also 
resulted in similar levels of p53 recruitment to the p21 promoter, while only a subset of 
these stresses resulted in sustained transcription of p21. Further challenging this 
hypothesis was the observation that p53 occupancy of target promoters measured in a p53 
ChIP microarray was static in response to different stresses, yet expression of these 
factors varied in a stress-specific manner (Wei et al., 2006). While the hypothesis may 
hold true when applied to individual target genes in specific contexts, it is an insufficient 
explanation for the specificity of p53 transcriptional regulation as a whole.  
Another early hypothesis arose out of the observation that different stress stimuli 
direct different arrays of post-translational modifications on p53, presenting the 
possibility that p53 transcriptional programs are a product of the relative prevalence of 
differentially modified p53 isoforms. A wealth of work on specific modifications of p53 
and their cell-fate preferences provides some support for this model. Tip60 and MYST 
acetyltransferases, for example, promote acetylation of lysine 120 of p53, an event that is 
critical for induction of p53-mediated apoptosis, but dispensable for growth arrest (Tang 
et al., 2006). Similarly, phosphorylation of serine 46 appears necessary for activation of 
the apoptotic gene p53AIP1, yet again dispensable for p21 activation (Oda et al., 2000). 
Many similar examples exist of modifications provided by specific factors which are 
necessary for activation of pro-apoptotic promoters, yet dispensable for cell-cycle arrest. 
These observations collectively raise the hypothesis that many modifications of p53 serve 
to provide a more strongly activating environment in the vicinity of low-affinity 
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promoters - either through increasing DNA-binding capabilities, p53 levels, or 
interactions with coactivators or other modulators. 
Again, however, recent evidence challenges the idea that the p53 ‘bar code’ of 
post-translational modifications provides a universal explanation for promoter selectivity 
in transcriptional activation. A pharmacological inhibitor of the p53-MDM2 interaction, 
nutlin-3 (Vassilev et al., 2004), has been widely used over the past few years to study the 
consequence of p53 stabilization in the absence of canonical stress stimuli. Using nutlin-
3, cell-fate decisions effected by p53 believed to require specific arrays of p53 
modifications were shown to occur even in the absence of these modifications (most 
significantly, serine-15)(Thompson et al., 2004). While the code may, and most likely 
does, contribute to p53-dependent transcriptional cell-fate decisions, it again is 
insufficient to fully account for the complexity of the p53 transcriptional response. 
Several recent analyses have suggested that the context of the promoter-associated 
transcriptional complexes control the regulation of certain p53 target genes at steps 
downstream of p53 and RNAPII binding(Gomes and Espinosa, 2010a). The most 
comprehensive analysis of transcriptional machinery binding at the p21 promoter 
(Donner et al., 2007) capitalizes on the observation that two robust stabilizers of p53 in 
HCT116 cells, nutlin-3 and UV, differentially activate p21 expression – nutlin-3 induces 
sustained transcription of p21, while UV produces a weak, transient elevation of p21 
levels. Observation by ChIP analysis indicated that p53 and RNAPII occupy the p21 
promoter to similar degrees in both scenarios, failing to explain the difference in p21 
expression status. Further analysis of transcriptional machinery present at the promoter 
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indicated that coactivator presence and histone acetylation throughout the locus was 
stimulated to the same extent under both conditions, suggesting that the p21 expression 
may be ‘primed’ in both cases, but some later regulatory step controls the final outcome 
of p53 binding at the p21 locus. Interestingly, a subset of factors present only during 
sustained p21 expression was identified, consisting of TFIIB, TFIIF, and CDK8. This 
evidence suggests that, at least for a subset of p53 target genes, that the specific 
configuration of the transcriptional apparatus is tightly regulated, and itself dictates the 
transcriptional outcome of activator binding. Further research will be necessary to 
elucidate how, precisely, the recruitment of these factors to the p21 promoter is regulated. 
Subsequent work from the Espinosa lab (Gomes and Espinosa, 2010b) 
unequivocally proves the model of p21 transcriptional activation cannot be extended to 
the exhaustive library of p53 target genes. High-resolution chIP and RNA analysis of the 
PUMA promoter revealed constant transcription, under basal conditions, of an 
unprocessed RNA of unknown function corresponding to the first 6 kb (first three exons) 
of the PUMA locus. Stimulation of PUMA expression by 5-fluorouracil (5-FU) effected 
little change in promoter occupancy of either p53, total RNAPII, phosphorylated 
RNAPII, or other assayed components of transcriptional complexes (in contrast to the 
p21 promoter, used for comparative purposes); yet transcription of the 6kb PUMA RNA 
was efficiently replaced by transcription  with full-length PUMA mRNA. Strikingly, 
chromatin marks normally delineating gene boundaries(H3K4-me3) or transcriptionally 
accessible chromatin (H3K9-Ac) were all absent downstream of the third exon even after 
expression of wild-type PUMA induced by 5-FU, delineating what the authors refer to as 
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an “intragenic chromatin boundary” regulating transcriptional elongation. Importantly, 
the chromatin architecture of the PUMA locus appears to be unusual based on genome-
wide analyses of chromatin marks throughout transcriptionally active chromatin 
(Guenther et al., 2007) – this example simply serves to further illustrate the complexity 
and heterogeneity of the p53 transcriptional response. 
The most likely scenario, as is often the case in the gradual reconciliation of early 
reductionist perspectives, is that all of the models above make a partial contribution to the 
complex regulation of p53-dependent transcription. The repertoire of p53 target genes has 
changed and expanded throughout evolution, and these loci have evolved accordingly in 
different genomic regions at different times. The data seem to currently support the 
hypothesis that induction of p53 target genes is regulated at many steps after p53 binding 
for high-affinity promoters, whereas induction of low-affinity promoters seems to be 
generally regulated at steps following RNAPII binding. Additionally, evidence suggests 
that the architecture of the core promoter is dependent upon genomic context, and that the 
core promoter itself regulates kinetics of RNA expression in a largely activator-
independent manner (Li et al., 2009). To fully explain the functional diversity of the p53 
transcriptional response, continuing research dissecting the structural and functional 
elements of each p53-responsive promoter will be necessary. 
 In addition to the well-defined role of p53 as a transcriptional activator, a subset 
of genes containing p53 response elements are repressed by p53 (Riley et al., 2008). 
Transcriptional repression by p53 impacts a similarly broad scope of cellular processes as 
transcriptional activation, but are broadly consistent with the role of p53 as a tumor 
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suppressor; c-myc, surviving, cyclin B2, and the stem-cell marker Nanog are examples of 
growth-promoting or proto-oncogenic loci repressed by p53(Wang et al., 2010). 
Precisely how an outcome of activation or repression by p53 is achieved on target 
promoters is an open question; however, some evidence suggests that the number, 
orientation, and sequence of p53 REs present in repressed genes may influence the 
outcome of p53-binding (Johnson et al., 2001; Murphy et al., 1999). Several analyses also 
suggest that spacer length may contribute significantly to p53 transactivation or 
repression potential – experimental alteration of spacer length has been shown to 
modulate both promoter occupancy and activation of p21 and surviving by p53 (Hoffman 
et al., 2002; Jordan et al., 2008); importantly, however, little correlation appears to exist 
between spacer length and activation versus repression when assayed on minimal 
promoters, suggesting that promoter context is critical in determining the transcriptional 
outcome of p53 binding. 
p53 is believed to biochemically mediate transcriptional repression through one or 
more of several means – occlusion of trans-acting activator binding-sites by p53, 
recruitment of transcriptional corepressors such as histone deacetylases (HDACs), or 
squelching of transcriptional activators such as the TATA-box binding protein (TBP) 
(Seto et al., 1992). While some correlative evidence exists supporting these modes of 
regulation in p53-mediated repression, associations are far from absolute, implying that 
additional, as yet undetermined factors impact regulation of p53-mediated activation 
versus repression. 
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Transcription-independent Functions of p53 
Mitochondrial Apoptosis 
 A well-characterized outcome of p53 activation in many contexts is apoptosis. 
Because p53 transactivates a multitude of pro-apoptotic genes, it was reasonably assumed 
that the apoptotic potential of p53 rested upon its activity as a transcription factor. In 
retrospect, however, it had been observed that p53 exhibits apoptotic activities in the 
presence of transcriptional inhibitors (Caelles et al., 1994) and, further, that 
transcriptionally-inactive p53 mutants maintain some apoptotic activity (Haupt et al., 
1995). Mounting evidence suggests that p53 exerts its transcription-independent 
apoptotic activities through localization of a mono-ubiquitinated pool of p53 to the 
mitochondria where, through complexing with anti-apoptotic Bcl-2 family members 
through the p53 DNA-binding domain, it promotes the release of cytochrome C, thereby 
promoting apoptosis (Marchenko et al., 2007; Mihara et al., 2003). In hindsight, this 
function of p53 may serve as an additional explaination for the higher propensity of 
tumors to inactivate p53 through DNA-binding domain mutations rather than 
transactivation domain mutations. 
 
DNA-damage repair 
 As in the case of apoptosis, p53 transactivates a wide array of genes contributing 
to DNA repair, but appears to play an additional direct role in transcription-coupled repair 
of some DNA lesions. A non-sequence-specific DNA-binding activity p53 likely serves to 
recruit chromatin remodeling factors such as p300 to sites of DNA-damage, relaxing 
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local chromatin conformation and allowing nucleotide excision repair (NER) factors to 
access damaged DNA (Rubbi and Milner, 2003). Another explanation not mutually 
exclusive with direct DNA-binding of p53 to sites of damage is that p53 associates with 
two subunits of the NER helicase TFIIH, XPB and XPD, at sites of DNA damage to 
direct accessibility of repair factors. p53 inhibits the helicase activity of TFIIH through 
direct interaction with the XPB helicase domain, potentially allowing the DNA-
associated complex to ‘lock’ into a state where it can nucleate an active NER complex 
and allow repair to proceed (Wang et al., 1995). 
 
Concluding Remarks 
 For over 30 years, p53 has been the subject of intense research, being found to 
have roles in nearly every facet of human physiology. Recent analyses suggest that p53 is 
the most mutated gene in human cancer, highlighting the critical role of its inactivation in 
tumorigenesis. How p53 coordinates the various processes that contribute to tumor 
suppression, and even the nature of the processes themselves, remains a topic of intense 
research and debate.  
A piece of the puzzle critical to our understanding of p53, and transcription in 
general, is how sequence-specific transcription factors accurately regulate activation of 
specific sets of target promoters under specific conditions. While post-translational 
modifications of p53, and modulation of p53 complexes and stability play an important 
role in this selectivity, an additional level of complexity exists after p53 binding to its 
cognate sequences at the promoter itself. It will also be of critical importance to better 
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define how upstream activating signals such as DNA-damage or ARF result in the 
activation of a highly specific p53-dependent physiological program. The work presented 
herein aims to define the P/CAF acetyltransferase as a critical regulator of both p53 
stabilization in response to p14ARF and, independently, a mediator of histone acetylation 
critical for p21 induction in response to a wide panel of p53-activating stresses. 
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Chapter II 
The Histone Acetyltransferase P/CAF Regulates p21 Transcription Through Stress-
induced H3K14 Acetylation 
 
Abstract 
 Initiation of transcription by sequence-specific transcription factors is facilitated, 
in part, by one or more histone acetyltransferases (HATs). Several HATs, including p300, 
CBP,  PCAF, and GCN5 have been implicated in the activation of p53-dependent 
transcription. Here we show that P/CAF is a critical regulator of p53-dependent p21 
expression in response to a wide variety of genotoxic stresses. P/CAF was required for 
the transactivation of p21 expression by exogenous p53 in p53-null cells. P/CAF was also 
critical for p21 expression induced by nutlin-3, DNA-damaging agents, and p14ARF 
expression; suggesting a role for P/CAF in control of p21 expression in response to a 
wide range of cellular stresses. Surprisingly, transcriptional activation of p21 by the p53 
K320R mutant was also dependent on P/CAF, suggesting that the role for P/CAF in p21 
induction is independent of p53 K320 acetylation, a previously suggested target of 
PCAF-mediated acetylation. ChIP analysis of the p21 promoter also indicated that 
promoter occupancy by p53 was not altered by P/CAF knockdown, but that acetylation of 
H3K14 stimulated by p53 in H1299 cells was dependent upon P/CAF. Together our 
experiments indicate that P/CAF is required for full p53-directed transcription of p21 in 
part through regulation of stress-responsive histone 3 acetylation at the p21 promoter. 
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Introduction 
 Cellular responses to aberrant activation of proto-oncogenes in metazoans 
constitute a vital defense against neoplastic transformation, and are frequently lost or 
deregulated in cancer. The tumor suppressor p53 is mutated in about half of all cancers 
and is believed to be functionally antagonized in most or all cancers retaining wild-type 
p53. Tumor suppressive activities of p53 are achieved through both transcription-
dependent and independent coordination of an array of cellular responses to various 
genotoxic stresses. Among the well-characterized transcriptional targets of p53 is the 
CDK-inhibitory protein p21, which is upregulated, often in a p53-dependent manner, in 
response to many physiologic stresses and results in a transient or sustained cell-cycle 
arrest. More recently, the p53-p21 signaling circuit has been shown to act as a barrier to 
both the generation of induced pluripotent stem (iPS) cells (Banito et al., 2009; Hong et 
al., 2009; Li et al., 2009), and tissue regeneration in mice (Bedelbaeva et al., 2010), 
highlighting the importance of developing a complete understanding of p21 regulation. 
 Histone/protein acetyltransferases (HATs) play a vital role in regulating 
transcription by acetylating histone tails, which in turn is believed to negatively regulate 
histone-nonhistone interactions and enhance chromatin accessibility of other transcription 
factors and adaptors. Additionally, many HATs directly regulate stability or activity of 
transcription factors, such as p53, through acetylation. Perhaps unsurprisingly then, some 
histone acetyltransferases (HATs) also harbor tumor suppressor activity and represent a 
promising class of therapeutic targets. 
 Among HATs known to act on p53 and enhance its transcriptional activity is the 
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p300/CBP-associated factor P/CAF (Di Stefano et al., 2005a; Liu et al., 1999). A member 
of the GNAT (GCN5-related N-acetyltransferase) family of protein acetyltransferases, 
P/CAF was originally identified as a factor displaced from p300/CBP-containing 
complexes after expression of the adenoviral oncoprotein E1A (Yang et al., 1996). The 
P/CAF complex is known to acetylate histones and various transcriptional regulators 
(Ogryzko et al., 1998), and has been shown to modulate activities of several tumor 
suppressors and oncogenes. Functional and structural characterization of P/CAF 
acetyltransferase activity indicates that K14 of histone H3 is the preferred substrate for 
this activity, and this residue appears to play a critical role in promoting the association of 
histone H3 with P/CAF (Poux and Marmorstein, 2003; Schiltz et al., 1999). 
 A direct role for P/CAF in p53 signaling has been previously suggested but is 
incompletely understood. Several reports using in vitro and overexpression analyses 
suggest that P/CAF is capable of directly acetylating p53 at lysine 320 and enhancing its 
site-specific DNA-binding activity, and that acetylation of this site increases after UV 
irradiation (Le Cam et al., 2006; Liu et al., 1999). Mass spectrometric analysis of p53 
fragments acetylated in vitro by p300 and PCAF indicates that lysine-320 is indeed an in 
vitro substrate of P/CAF acetyltransferase activity (Sakaguchi et al., 1998). Several 
studies also utilize p53 acetyl-lysine specific antibodies to detect acetylated forms of p53 
under various conditions, but cross-reactivity of these antibodies with other residues is a 
common caveat of this method. Therefore, in vivo and cell culture models describing the 
nuanced functions of P/CAF in p53 acetylation and activity are lacking.  
 Here we show that, under a variety of p53-activating stress conditions and cell 
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types, P/CAF is critical for p21 expression and p53-dependent cell-cycle arrest. This role 
of P/CAF in p21 expression is transcriptional, as shown by a P/CAF-dependent increase 
in p21 transcripts in p53-transfected H1299 cells by real-time rtPCR. Ablation of P/CAF 
by siRNA is associated with a loss of acetylation of H3K14, a previously described 
P/CAF-directed modification commonly associated with transcriptional activation, at the 
distal p53 response element of the p21 promoter. Levels of total RNA polymerase II 
loaded at the proximal promoter are correspondingly lower in the absence of P/CAF; 
furthermore, RNA polymerase II levels downstream of the proximal promoter correlate 
with the expression status of p21. These data indicate that P/CAF regulates p53-
dependent p21 activation through histone acetylation at the p21 promoter, which creates 
an environment permissive for p21 transcription. Additional experiments will be required 
to determine which, if any, other p53-responsive promoters require P/CAF for their 
transcriptional activation. 
 
Results 
 Two reports (Mellert et al., 2007; Sekaric et al., 2007a) indicate that p53 is 
acetylated in response to p14ARF expression in both the DNA-binding domain and the 
p53 C-terminus. To address the role of known p53 coactivators in p14ARF-directed p53 
acetylation and activation, we surveyed the roles of p300, CBP, and P/CAF by siRNA-
mediated depletion in U2OS cells. In line with previous reports (Grossman et al., 1993; 
Shi et al., 2009a), p300 and CBP appeared to negatively regulate p53 stability under basal 
conditions, presumably through their roles as E4 ubiquitin ligases (ubiquitin ligases 
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which recognize already mono-ubiquitinated proteins as substrates); strikingly, however, 
P/CAF depletion completely prevented stabilization of p53 and induction of p21 in 
response to ARF (Figure 2.1A). To rule out the possibility that this result was cell-type 
specific, we repeated the experiment in hTERT-immortalized, diploid RPE1 cells; again, 
P/CAF was necessary for ARF-directed p53 stablization and p21 induction (Figure 2.1B). 
To determine the effects of P/CAF depletion on the cell-cycle distribution of ARF-
transfected U2OS or RPE1 cells, cell populations were stained with propidium iodide and 
analyzed by flow cytometry (Figure 2.2). As expected, p14ARF transfection induced a 
potent cell-cycle arrest in both U2OS and RPE1 cells; however, in P/CAF-depleted 
populations, p14ARF failed to induce a cell-cycle arrest.   
 To determine whether the involvement of P/CAF in p53 activity is specific to 
ARF, we examined the p53 and p21 response to a variety of p53-activating stresses in the 
presence or absence of P/CAF. First, we noticed that depletion of P/CAF by siRNA in 
p53-transfected H1299 cells resulted in a dramatic reduction in p21 levels (Figure 2.3A). 
We also tested the impact of P/CAF knockdown on a variety of stresses which induce p21 
in a p53-dependent manner. Use of nutlin-3, a nanomolar competitive inhibitor of the 
MDM2-p53 interaction, which stabilizes endogenous p53 in U2OS cells, is known to 
result in induction of p21 (Vassilev et al., 2004); as expected, both p53 and p21 levels 
increased in response to nutlin-3 – however, while nutlin-3 also resulted in p53 
stabilization in the absence of P/CAF, no corresponding increase in p21 levels was 
observed (Figure 2.3B). To ensure that the inability of this stress to culminate in p21 
induction did, in fact, impact the cell-cycle distribution of these populations, we again 
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examined PI-stained cell populations by flow cytometry. While nutlin-3 treatment of 
U2OS cells resulted in a cell-cycle arrest, the P/CAF-depleted population again failed to 
undergo a comparable arrest (Figure 2.3E).  
 To observe a more physiologically relevant activator of p53 stress responses, we 
turned to ultraviolet radiation and the DNA-damaging agent Doxorubicin, which causes 
the accumulation of double-strand breaks and potently activates p53 signaling. After 
exposure to 100nM Doxorubicin for 24 hours (Figure 2.3C) or 20 J/m^2 UV (Figure 
2.3D), control-siRNA expressing U2OS cells exhibited increased p21 levels, whereas 
P/CAF siRNA-expressing cells did not, despite a similar increase in p53 levels in both 
control or P/CAF-siRNA expressing cells. 
 To determine whether the loss of p21 induction led to changes in cell-cycle 
distribution, we examined DNA content of PI-stained cell populations of ARF-transfected 
or nutlin-treated cells using flow cytometry. In both ARF-expressing U2OS and RPE1 
cells expressing control siRNA, the population showed a striking absence of S-phase 
cells, indicating a potent cell-cycle arrest; whereas these ARF-expressing populations 
failed to undergo cell-cycle arrest in the absence of P/CAF due to a loss of p21 (Figure 
2.2A). Similar results were seen with nutlin-3 treatment, after which cells depleted for 
P/CAF failed to undergo a cell-cycle arrest (Figure 2.3E). 
 P/CAF is known to function as a transcriptional coactivator for several factors 
through its ability to acetylate histone and non-histone factors; however, P/CAF has also 
been recently shown to exhibit intrinsic E3 ligase activity toward MDM2 (Linares et al., 
2007). An examination of steady-state levels of MDM2 and p53 in P/CAF-depleted 
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U2OS cells revealed no appreciable change in the levels of p53 or MDM2 (Figure 2.7). 
Therefore we wished to investigate whether p21 mRNA expression levels were being 
regulated by P/CAF. We performed quantitative rtPCR on H1299 cells transfected with a 
vector or wild-type p53 in combination with either control or P/CAF siRNA. Results of 
this experiment indicate that p21 mRNA is indeed upregulated following transfection of 
p53, but p21 transcripts remain unchanged in P/CAF siRNA-expressing cells as 
compared to the vector control, consistent with P/CAF exerting control over p21 
expression through a transcriptional mechanism. Importantly, transcription of transfected 
p53 and endogenous β-actin are both unaffected by the absence of P/CAF (Figure 2.4), 
indicating that the impact of P/CAF knockdown on p21 expression is not a consequence 
of global effects on general transcription. 
 Because P/CAF has a previously described role in acetylation of p53 K320, we 
tested whether a p53 K319-321R mutant is competent for transactivation of p21 and, if 
so, whether P/CAF is also critical for p21 expression in this context. We found that p53 
K319-321R stimulates p21 expression to a level comparable to wild-type p53, and that 
P/CAF is indeed critical for p21 expression driven by p53 K319-321R (Figure 2.6). 
These results indicate that, in addition to acetylation of p53 K320, P/CAF plays an 
additional, and critical, role in p53-dependent p21 expression.   
 Because P/CAF ablation modulates p21 transcription by both wild-type and 
K319-321R p53, we reasoned that P/CAF may be functioning through its histone 
acetyltransferase activity to regulate p21 transcription. P/CAF exhibits well-characterized 
HAT activity toward several lysines of histone 3, most potently lysine 14 (H3K14) 
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(Marmorstein and Berger, 2001) and, by global chIP-seq studies in wild-type and P/CAF-
null MEFs, lysine 9 (Jin et al., 2011). To determine whether H3K14 acetylation in 
response to p21-inducing stimuli (p14ARF expression in U2OS cells or transfected p53 
in H1299 cells) is impacted by loss of P/CAF, we analyzed by chromatin 
immunoprecipitation (chIP) the occupancy of the distal p53-response element of the p21 
promoter by acetylated H3K14. In both ARF-transfected U2OS cells (Figure 2.5A) and 
p53-transfected H1299 cells (Figure 2.5B), H3K14 acetylation is stimulated in relation to 
untransfected cells; however, cells expressing P/CAF siRNA exhibit only baseline levels 
of H3K14 acetylation, which correlate closely with p21 expression status in our 
experiments. 
 We further reasoned that if P/CAF directly acetylates H3K14 to modulate p21 
expression, and is not indirectly facilitating binding of other HATs to the promoter, this 
should be dependent upon P/CAF HAT activity. Using an internal deletion mutant of 
P/CAF deficient in HAT activity (Jiang et al., 1999), we introduced silent mutations into 
the siRNA-hybridizing region of the P/CAF ORF and rescued P/CAF knockdown with 
either a wild-type or HAT-deficient P/CAF allele. As expected, in H1299 cells expressing 
exogenous p53, co-expression of P/CAF siRNA with wild-type P/CAF restored p21 
expression, whereas co-expression of P/CAF siRNA with the HAT mutant did not (Figure 
2.5C). This experiment clearly indicates that P/CAF HAT activity is necessary for p21 
expression in response to stress.  
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Figure 2.1: P/CAF is necessary for expression of p53 and induction of p21 in 
response to p14ARF in U2OS and RPE1 cells.  
 
1X10^6 U2OS (Figure 2.1A) or RPE1 (Figure 2.1B) cells were plated and transfected 
with Lipofectamine 2000 after 24h with 10nM indicated siRNA and 1ug pcDNA3-
p14ARF or pcDNA3 vector with 1ug salmon-sperm DNA (1.6ug DNA : 1uL 
Lipofectamine) and harvested 48h post-transfection. Cells were lysed in SDS lysis buffer 
(50mM Tris pH 6.8, 2% SDS) for SDS-PAGE analysis (Fig. 1A-1B). Cells were 
harvested 48hr post-transfection and lysed in 300-500uL 2% SDS with 50mM Tris 
pH6.8. Protein concentrations were determined using the BCA assay kit, 20ug protein 
loaded in each well and separated by SDS -PAGE. 
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Figure 2.1: P/CAF is necessary for expression of p53 and induction of p21 in response to 
p14ARF in U2OS and RPE1 cells. 
 
      
                                
 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ARF 
siRNA neg p300 CBP PCAF 
- - - + + + + - 
p53 
actin 
p21 
MDM2 
PCAF E8 
p14ARF 
CBP 
p300 
RPE1 B 
54 
 
Figure 2.2: P/CAF is necessary for ARF-induced cell-cycle arrest in U2OS and RPE1 
cells. 
 
1X10^6 U2OS (Figure 2.2A) or RPE1 (Figure 2.2B) cells were plated and transfected 
with Lipofectamine 2000 after 24h with 10nM indicated siRNA and 1ug pcDNA3-
p14ARF or pcDNA3 vector with 1ug salmon-sperm DNA (1.6ug DNA : 1uL 
Lipofectamine) and harvested by scraping 48h post-transfection. After 3 5mL PBS 
washes the cell pellet was fixed in ice-cold EtOH, stained with propidium iodide 48h 
later for flow cytometric analysis. 20,000 events were taken, including any sub-G1 
population. 
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Figure 2.2: P/CAF is necessary for ARF-induced cell-cycle arrest in U2OS and RPE1 
cells. 
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Figure 2.3: PCAF is required for p53-dependent p21 expression in a cell and stress-
autonomous manner. 
 
U2OS cells were plated at a density of 4x10^5 per 60mm plate or 1x10^6 per 100mm 
plate. H1299 cells were plated at a density of 6x10^5 per 60mm plate or 1.5x10^6 per 
100mm plate. Cells were transfected and harvested for SDS-PAGE or flow cytometry as 
described above. Nutlin-3-treated U2OS cells were exposed to 5uM nutlin-3 for 16 hours 
prior to lysis or fixation. Doxorubicin-treated U2OS cells were exposed to 1uM 
Doxorubicin for 16 hours prior to lysis. UV-irradiated U2OS cells were dosed with 20 
J/m^2 UVC prior to lysis using a Stratagene Stratalinker. 
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Figure 2.3: PCAF is required for p53-dependent p21 expression in a cell and stress-
autonomous manner 
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Figure 2.4: P/CAF is a transcriptional regulator of p21 expression. 
 
H1299 cells were plated and transfected as described in previous figures, and total 
cellular RNA was purified using RNeasy kits (Qiagen). cDNA was generated using 
AffinityScript reverse transcriptase (Agilent Technologies). 1uL cDNA was amplified in 
triplicate using SYBR green and primers specific to β-actin, p21, or p53. 
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Figure 2.4: P/CAF is a transcriptional regulator of p21 expression 
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Figure 2.5: P/CAF regulates H3K14 acetylation at the p21 promoter. 
A,B) Cells were plated and transfected as described above. Prior to lysis, cells were 
crosslinked with 1% formaldehyde for 10 minutes. Chromatin immunoprecipitations 
were performed as described in the Materials and Methods section. PCR was performed 
by amplifying the distal p53 response element of the p21 promoter with GoTaq 
polymerase (Roche) for 33 cycles for all samples. C) H1299 cells were transfected, lysed 
and separated by SDS-PAGE as in Figure 2.1. ΔHAT was generated by using PCR-based 
mutagenesis to generate a pCMV-P/CAF plasmid harboring an in-frame internal deletion 
of amino acids 608-628, and four silent mutations in the siRNA-hybridizing region of the 
open reading frame. 
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Figure 2.5: P/CAF regulates H3K14 acetylation at the p21 promoter 
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Figure 2.6: P/CAF regulates p21 expression independently of p53 K320 acetylation. 
 
H1299 cells were transfected, lysed, and separated by SDS-PAGE as described above. 
WT indicates overexpression of a wild-type pCMV-p53 construct; 3KR denotes a pCMV-
p53 construct in which lysines 319-321 have been mutated to arginine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
63 
 
Figure 2.6: P/CAF regulates p21 expression independently of p53 K320 acetylation 
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Figure 2.7: siRNA-mediated ablation of P/CAF does not alter basal levels of 
endogenous MDM2 or p53. 
 
U2OS cells were transfected, lysed, and separated by SDS-PAGE as previously 
described. The three P/CAF siRNA sequenced used in this experiment are as follows: 
PCAF-1: UCG CCG UGA AGA AAG CGC Att 
PCAF-2: GGU GGU AUC UGU UUC CGU Att 
PCAF-3: GGA GUC UUG UAA  AUG UAA Utt 
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Figure 2.7: siRNA-mediated ablation of P/CAF does not alter basal levels of endogenous 
MDM2 or p53 
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Figure 2.8: P/CAF Is Dispensable For p16-induced Arrest in U2OS Cells. 
 
U2OS cells were transfected with 1ug pcDNA3-p16 or pcDNA3 with 4ug salmon-sperm 
DNA and 10nM indicated siRNA. Cells were harvested by scraping in PBS and washed 3 
times with PBS. ¾ of the cell pellet was fixed in ice-cold 95% EtOH for at least 48 hours 
prior to PI staining and flow cytometry. The remaining ¼ of the cell pellet was lysed in 
SDS lysis buffer (2% SDS, 50mM Tris pH 6.8) for analysis by western blot. 
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Figure 2.8: P/CAF Is Dispensable For p16-induced Arrest in U2OS Cells 
 
 
 
 
 
 
                                     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
68 
 
Discussion 
 Together, our data indicate that P/CAF is necessary to facilitate the stress-induced 
activation of the p21 promoter by creating a chromatin environment permissive for 
transcriptional activation. We have shown that P/CAF histone acetyltransferase activity is 
necessary for p53-directed p21 transcription in several cell types and in response to 
several stimuli. Loss of H3K14 acetylation at the p21 promoter is observed in the absence 
of P/CAF in p53-transfected H1299 cells, as well as ARF-transfected or nutlin-3 treated 
U2OS cells. This lack of histone acetylation correlates tightly with p21 expression status, 
mRNA levels. The impact of P/CAF on p21 expression requires an intact P/CAF HAT 
domain, suggesting that these effects are mediated by PCAF acetylase activity, and not 
simply through an interacting protein. This work defines a critical role for PCAF in p53-
p21 signaling.  
 Significantly, these experiments provide a plausible explanation for previously 
described tumor suppressive functions of P/CAF. Despite the normal development of 
P/CAF-null mice (likely due to compensation by GCN5), P/CAF is downregulated 
through methylation or allelic loss in a variety of cancers (Perez et al., 2010; Zhu et al., 
2009), notably, induces a G1 arrest and inhibits soft agar growth and tumorigenesis upon 
its reintroduction to cell lines established from these tumors. While the levels of several 
key cell-cycle regulators including p21 were evaluated in these studies, the mechanistic 
role of P/CAF in this activity was not explored further. Our data suggest that expression 
of p21 in response to a panel of genotoxic stresses specifically requires P/CAF HAT 
activity. 
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It has long been suggested that histone acetylation is permissive for 
transcriptional activation (Kuo and Allis, 1998; Sterner and Berger, 2000). However, 
mounting evidence indicates that histone acetylation at a promoter does not dictate the 
ultimate transcriptional status at a locus; indeed, several examples of histone acetylation 
at a transcriptionally silent p21 locus have been described (Donner et al., 2007; Gomes 
and Espinosa, 2010a); however, we are unaware of any reports in which p21 transcription 
proceeds in the absence of activating histone marks. Our data suggest a model in which 
recruitment of P/CAF HAT activity to the p21 locus by a transcriptional activator, in this 
case p53, allow for the occurence of subsequent downstream events that ultimately lead 
to elongation by the RNA pol II complex, which published works suggest is highly 
correlated with the transcriptional status of the p21 promoter. A report from the Espinosa 
lab (Donner et al., 2007) utilizing a high-resolution chIP for various factors at the p21 
promoter under distinct stress conditions indicates that UV irradation of HCT116 +/+ p53 
cells promotes accumulation of p53, acetylated histones, and certain general transcription 
factors at the promoter despite the gene remaining transcriptionally silent (and 
characterized by a lack of elongating pol II). In comparison, in nutlin-treated cells the 
accumulation of additional factors from the Mediator complex, as well as cyclin-C/CDK8 
occurs along with elongating and serine-2 phosphorylated RNA pol II and, accordingly, 
p21 is expressed. 
While we have clearly defined a novel role for P/CAF in p53-dependent p21 
transcription through histone acetylation, the role of P/CAF in p53 signaling may be far 
broader. While we utilized a K319-321R p53 mutant to prove that P/CAF has additional 
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activities impacting p53, it does not rule out the possibility that under certain stress 
conditions or in specific cell contexts, K320 is a physiologically relevant acetylation 
target. Acetylation of either K320 or K382 is associated with  occupancy of a unique set 
of p53-responsive promoters, interaction with a unique set of p53 coactivators, and 
differential roles in p53 localization (Knights et al., 2006). Additionally, one report 
suggests that P/CAF affects p53 signaling through modulation of human MDM2 (HDM2) 
stability by an E3 ubiquitin ligase activity intrinsic to P/CAF (Linares et al., 2007); 
however, using U2OS cells we observed no increase in steady-state MDM2 in PCAF-
depleted cells (Figure 2.7). It is possible that P/CAF does harbor E3 ligase activity toward 
MDM2, but under the conditions  in which these experiments were performed, P/CAF 
did not alter MDM2 levels. This raises the possibility that some additional culture 
stress(es) may be present in certain conditions which contribute to P/CAF E3 ligase 
activity toward MDM2. 
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Materials and Methods 
Reagents 
pCDNA-p53, pCDNA3-p14ARF, and pCDNA3 vectors were used in 
transfections. pCI-PCAF lacking the HAT domain (Δ608-629) and pCMV-p53 K319-
321R were created by site-directed PCR mutagenesis, and both entire reading frames 
were sequenced to rule out the possibility of secondary mutations. Four silent mutations 
were introduced into the siRNA-hybridizing sequence to allow expression in the presence 
of siRNA. siRNA sequences used are as follows: SiRNA sequences: p300 – 
CAGAGCAGUCCUGGAUUACtt ; CBP - AAUCCACAGUACCGAGAAAUGUU ; 
PCAF – UCGCCGUGAAGAAAGCGCAtt ; PCAF-2 – 
GGUGGUAUCUGUUUCCGUAtt ; PCAF-3 – GGAGUC UUGUAAAUGUAAUtt 
 
Cell Lines and Antibodies 
RPE1, U2OS, and H1299 cells were grown under conditions suggested by ATCC. 
Antibodies used to detect endogenous protein levels were as follows: PCAF was detected 
with mouse monoclonal antibody E8 (Santa Cruz), p300 with rabbit polyclonal N-15 
(Santa Cruz), CBP with rabbit polyclonal E14 (Santa Cruz) MDM2 with rabbit 
polyclonal antibody N20 (Santa Cruz), p53 with mouse monoclonal DO-1 or rabbit 
polyclonal FL-393 (Santa Cruz), p21 with mouse monoclonal 6B6 (Upstate), actin with 
rabbit polyclonal (Sigma), and acetylated H3K14 with (Active Motif #39599) 
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Transfections 
RPE1 or U2OS cells were plated at a density of 1x10^6 cells / 10 cm dish 24 
hours prior to transfection. H1299 cells were plated at a density of 1.5x10^6 cells / 10 cm 
dish 24 hours prior to transfection. Cells were then transfected with 10nM siRNA 
targeting p300, CBP, PCAF, or a negative control siRNA (Ambion) using Lipofectamine 
2000 (Invitrogen). After 24 hours, cells were transfected again with 10nM siRNA, 1ug 
pcDNA3-p14ARF or pcDNA3, and 4ug salmon-sperm DNA. Cells were harvested 48 
hours after the second transfection, lysed using 300uL SDS buffer (2% SDS, 50mM Tris 
pH 6.8), boiled for 5 minutes and stored at -80C. Protein concentrations were determined 
using a BSA standard curve, and proteins were separated by SDS-PAGE and blotted 
using antibodies described above. 
 
UV Irradiation, Nutlin-3, or Doxorubicin treatment 
 U2OS cells were plated and transfected as described above. Cells were treated 
with 5uM nutlin-3 for 16 hours prior to lysis/fixation, 20 J/m^2 UVC 24 hours prior to 
lysis/fixation, or exposed to 1uM Doxorubicin for a 16-hour duration prior to 
lysis/fixation. 
 
Flow cytometry and PI staining 
Cells were harvested 48 hours after second transfection by scraping and fixed in 
75% EtOH for 24-72 hours at -20°C. Cells were stained with 50ug/mL propidium iodide 
in PBS and treated with 100uL of 100mg/mL RNAse prior to flow cytometric analysis by 
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the UMMS FACS core facility. Data was analyzed using FlowJo software (Tree Star, 
Inc.) 
 
mRNA Isolation and Quantitative Real-time PCR 
 Total cellular RNA was isolated using RNAeasy kits (Qiagen) as described in the  
protocol. cDNA was then generated using AffinityScript reverse transcriptase (Agilent 
Technologies). 1uL cDNA was amplified in triplicate using SYBR green and primers 
specific to β-actin, p21, or p53. p53 and p21 signal was normalized to actin mRNA. 
 
Chromatin immunoprecipitation 
 U2OS cells were plated into 8 15cm dishes at a density of 2.5x10^6 cells / 15cm 
dish. H1299 cells were plated into 8 15cm dishes at a density of 4x10^6 cells / 15cm dish. 
After transfections or nutlin-3 treatment as described above, cells were crosslinked with  
formaldehyde at a final concentration of 1% for 10 minutes, rotating at room temperature. 
Cells were washed 3 times with 15mL cold PBS after crosslinking. Cells were scraped ito 
15mL conical tubes with 10mL PBS and centrifuged at 4,000rpm for 5 minutes. Nucleii 
were concentrated by lysing cell pellets in 10mL nuclear isolation buffer (5 mM PIPES 
pH 8.0, 85mM KCl, 0.5% NP-40) for 20 minutes and centrifuging at 2,000rpm for 5 
minutes. Nuclear pellets were lysed in 1mL nuclear lysis buffer (50mM Tris pH 8.0, 
10mM EDTA, 1% SDS) for 30 minutes on ice. Lysates were sonicated in an EtOH-ice 
bath for five 10-second pulses at an amplitude of 8 (out of 15). SDS was precipitated out 
by leaving on ice for 1 hour, supernatant was removed and DNA quantified at A260. 
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After diluting 1:1 in dilution buffer (16.7mM Tris pH 8.0, 167mM NaCl, 0.01% SDS, 
1.1% Triton X-100), 150ug chromatin was pre-cleared for 1 hour at 4°C using 30uL 
Protein A and 30uL Protein G beads (Millipore) for each antibody used in each condition. 
Supernatant was removed after a 30 second spin at 1,000rpm, relevant chIP antibodies 
were added to each sample, and samples were rotated overnight at 4°C. 30uL Protein A 
and 30uL Protein G beads were added to each sample for 2 hours at 4°C to allow binding. 
Four 1mL high-salt washes (50mM HEPES pH 7.9, 500mM NaCl, 1mM EDTA, 0.1% 
SDS, 1% Triton X-100, 0.1 DOC) were performed, followed by two washes with TE 
buffer. TE buffer was aspirated, and beads were suspended in 300uL elution buffer 
(50mM Tris pH 8.0, 10mM EDTA, 1% SDS) and 1uL Proteinase K (20ug/mL), and 
eluted for 1 hour in a 55°C heat block. Crosslinks were then reversed by incubating 
samples overnight in a 65°C heat block. DNA was purified using Qiagen PCR 
Purification columns and eluted in 50uL ddH2O. PCR was performed by amplifying the 
distal p53 response element of the p21 promoter with GoTaq polymerase (Roche) for 33 
cycles for all samples. 
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Chapter III 
Critical Requirement for P/CAF in p14ARF Signaling 
 
  
Abstract 
p14ARF activation has recently been shown to induce acetylation of p53 within 
both the DNA-binding domain and the C-terminal regulatory region. In an effort to 
identify the HAT or HATs which mediate this effect and to elucidate the importance of 
this modification in p14ARF signaling, we expressed specific siRNA oligos against 
multiple HATs implicated in the regulation of p53 function. In both human tumor cells 
and hTERT-immortalized RPE1 cells, siRNA-mediated ablation of p300 and CBP 
increased basal p53 levels and p21 activation and induced spontaneous cell cycle arrest 
while, surprisingly, knockdown of P/CAF prevented p14ARF-induced p53 and p21 
expression, as described in Chapter II. P/CAF ablation also prevented cell cycle arrest 
after transfection of p14ARF. This effect was dependent upon the HAT domain of P/CAF, 
as a P/CAF mutant lacking the HAT domain was unable to rescue effects of P/CAF 
ablation on p53 activity. Surprisingly, siRNA-mediated reduction of p300, CBP, or 
P/CAF resulted in a loss of C-terminal acetylation at lysine-382 and phosphorylation of 
serine-15, indicating that these modifications are not absolutely required for p53 
stabilization or activation, and further suggesting that the presence of all three HATs may 
be required for p53 phosphorylation and acetylation. Additionally, to rule out general 
effects of P/CAF knockdown on transcription and signaling, we demonstrate that p16-Rb 
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signaling is intact in the absence of P/CAF. These results were consistent in U2OS cells 
as well as non-transformed, hTERT-immortalized retinal pigment epithelial (RPE1) cells. 
To determine the manner in which P/CAF regulates p14ARF-dependent p53 stabilization, 
we performed co-immunoprecipitations of MDM2 with p14ARF and p53, and attempted 
to analyze the localization of these factors in the presence or absence of P/CAF. Co-
immunoprecipitation of MDM2 with p14ARF and p53 were unaffected by P/CAF 
knockdown. Additionally, immunofluorescence experiments examining the localization 
of MDM2 in the presence or absence of P/CAF were inconclusive, but this possibility 
certainly warrants further investigation. 
These experiments have defined the histone acetyltransferase activity of P/CAF as 
a critical and specific regulator of oncogenic stress signaling in human cells; in contrast, 
and in agreement with recent reports, p300 and CBP appear to play negative roles in p53 
stability and activity under non-stress conditions. Ongoing work will seek to determine 
precisely by what mechanism P/CAF modulates p53 stability and activity in response to 
p14ARF. 
 
Introduction 
Surveillance of proto-oncogene activation is controlled in metazoans in large part 
through the products of the INK4A locus. In many cancers harboring wild-type p53, 
inactivation of the INK4A locus through hypermethylation is frequently observed. This 
locus encodes two potent yet structurally and functionally distinct tumor suppressors – 
p16INK4a and p14ARF. While p16INK4a inhibits Cdk4/6-mediated phosphorylation of  
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Retinoblastoma(Rb) through direct binding to Cdk4/6, p14ARF acts in the p53 pathway 
in part by blocking the E3 ligase activity of MDM2 toward p53, thereby stabilizing p53.  
p14ARF also regulates p53 activity in part by modulating levels of acetylated p53 
(Zhang et al., 2006). Following induction of p14ARF signaling (Sekaric et al., 2007a), 
p53 is acetylated on several C-terminal lysines in a manner dependent upon the 
transcriptional adaptor ADA3. A recent report also suggests that p53 is acetylated within 
the DNA binding domain following induction of p14ARF signaling. A lysine within the 
p53 DBD was recently described as a target of the MYST/Tip60 family 
acetyltransferases, but it is yet unclear what factor(s) mediate this effect in response to 
p14ARF. Most importantly, the physiological importance of these modifications in 
p14ARF signaling is unknown.  
Transcriptional activation in eukaryotes is a highly complex and regulated process 
which is not completely understood. Eukaryotic chromatin structure presents a physical 
barrier to activation of transcription by regulating accessibility of the transcriptional 
machinery to specific loci. Transcription in response to various stimuli is often promoted 
by sequence-specific transcription factors which function to recruit coactivators, 
chromatin remodeling factors, and basal transcription factors to target promoters to 
facilitate transcriptional activation. Histone/protein acetyltransferases (HATs) play a vital 
role in regulating transcription by acetylating histone tails, which in turn is believed to 
positively or negatively regulate histone-nonhistone interactions and enhance 
accessibility of other transcription factors and adaptors, as well as regulate stability and 
activity of transcription factors through direct acetylation. 
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To date, p53 has been described as a substrate for several acetyltransferases; the 
coactivators p300 and CBP were first described to acetylate several C-terminal lysines of 
p53 and thereby enhance DNA-binding and transcriptional activation (Gu and Roeder, 
1997; Lill et al., 1997). P/CAF, a member of the GNAT (GCN5-related N-
acetyltransferase) family of protein acetyltransferases, was originally identified as a 
factor displaced from p300/CBP-containing complexes after expression of the adenoviral 
oncoprotein E1A. Purification of epitope-tagged P/CAF from HeLa cells identified 
several factors in the P/CAF complex including the transcriptional adaptor protein ADA3. 
 The role of P/CAF in p53 activity and stability is also incompletely understood. 
Several early reports using in vitro and overexpression analyses suggest that P/CAF is 
capable of directly acetylating p53 on lysine 320 and enhancing its site-specific DNA-
binding activity, and that acetylation of this site increases after UV irradiation (Le Cam et 
al., 2006; Liu et al., 1999). Mass spectrometric analysis of p53 fragments acetylated in 
vitro by p300 and P/CAF indicates that lysine-320 is indeed an in vitro substrate of 
P/CAF acetyltransferase activity (Sakaguchi et al., 1998). Several studies also utilize 
acetyl-lysine-p53 specific antibodies to detect specifically acetylated forms of p53 under 
various conditions, but crossreactivity of these antibodies with other residues is a 
common caveat of this method. Therefore, in vivo and cell culture models describing the 
function of P/CAF in p53 acetylation and activity are lacking.  
Here we present evidence that P/CAF is a critical and specific regulator of the 
ARF response in non-transformed human cells, whereas CBP and p300 are required to 
maintain a low level of latent steady-state p53 under basal conditions. 
79 
 
 
Results 
P/CAF is required for p14ARF-induced p53 stabilization.  
Because p53 acetylation is induced following p14ARF transfection, we reasoned 
that one or more HATs implicated in p53 activation is responsible for this effect. Several 
studies suggest that cellular HATs p300, CBP, and P/CAF play vital roles in p53 stability 
and activity. Therefore, siRNAs specifically targeting p300, CBP, or P/CAF were 
expressed both in U2OS cells and hTERT-immortalized RPE1 cells, then transfected with 
p14ARF or vector control. Surprisingly, ablation of CBP or p300 resulted in a drastic 
increase in basal p53 levels, suggesting negative roles for CBP and p300 in p53 stability 
consistent with previous reports; in contrast, ablation of P/CAF completely prevented 
stabilization of p53 after p14ARF transfection (Figure 2.1A-B). 
 
P/CAF is required for p14ARF-induced p21 induction and cell cycle arrest. 
To evaluate the biological effects of PCAF knockdown on p53 signaling, 
expression of two well-described transcriptional targets of p53 – p21 and MDM2 – was 
analyzed by western blot, and PI staining and flow cytometry were performed to examine 
cell cycle profile (Figure 2.2A-B). As expected, p21 and MDM2 expression closely 
correlated with p53 stabilization, indicating that stabilized p53 is capable of activating 
transcription under these conditions (Figure 2.1). Flow cytometric analysis of PI-stained 
populations indicates that p14ARF induces a potent cell cycle arrest, indicated by a 
complete loss of S-phase cells, which is prevented by PCAF knockdown (Figure 2.2A-
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B). 
 
Role of P/CAF in oncogenic signaling is specific to the p14ARF pathway and 
dispensable for p16INK4a-induced arrest.  
P/CAF, p300, and CBP each possess a wide array of substrates for their histone 
acetyltransferase activity, suggesting the possibility that loss of these coactivators could 
have global effects on transcription which could affect a myriad of signaling pathways. 
To provide evidence that the role of P/CAF is specific to p14ARF signaling, we evaluated 
the role of P/CAF in p16INK4a-induced cell cycle arrest. Interestingly, ablation of P/CAF 
in both U2OS and RPE1 cells did not prevent cell cycle arrest in either cell line following 
transfection p16INK4a (Figure 2.8); however, p16INK4a-induced cell cycle arrest in 
cells expressing P/CAF siRNA displayed a greater propensity to undergo arrest in the G1 
phase of the cell cycle, whereas G2 arrest predominated in cells expressing a control 
siRNA. 
 
Loss of p53 K382 acetylation and S15 phosphorylation following HAT depletion  
Because PCAF loss abolishes p53 signaling in response to p14ARF, we reasoned 
that a deficiency in PCAF-dependent acetylation could explain this effect. We probed 
lysates shown in Figure 2.1 with a monoclonal antibody specifically recognizing p53 
acetylated at lysine-382, one of the C-terminal lysines of p53 predominantly acetylated in 
response to stress. We attempted to normalize the amount of total p53 between samples as 
detected by the polyclonal antibody FL-393 following densitometric analysis (data not 
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shown). As we expected, acetylation of lysine-382 was not detected in PCAF siRNA-
treated samples following p14ARF transfection. Surprisingly, however, lysine-382 
acetylation was also lost in p300 and CBP siRNA-treated samples despite the previously 
observed potent cell-cycle arrest and robust activation of  p21 (Figure 3.1). These results 
indicate that acetylation of lysine-382 is not absolutely required for activation of p53. 
N-terminal phosphorylation is known to enhance interaction of p53 with HATs 
(Barlev et al., 2001; Sakaguchi et al., 1998), and p14ARF has been reported to function 
through ATM/ATR to effect p53 activation (Li et al., 2004; Rocha et al., 2005). Based on 
these observations, and the observation that p14ARF promotes p53 acetylation (which is 
often associated with S15 phosphorylation), we wished to determine whether S15 is 
phosphorylated in response to p14ARF and, if so, whether this effect was dependent upon 
p300, CBP, or P/CAF. As expected, p14ARF strongly induced phosphorylation of S15 in 
both U2OS and RPE1 cells. Surprisingly, however, we noted that phosphorylation was 
attenuated by depletion of p300, CBP, or P/CAF. While residual phosphorylation was 
detectable after knockdown of p300 or CBP, none was detectable following P/CAF 
knockdown (Figure 3.2).  
 
The MDM2 interaction with p14ARF or p53 is unaffected by P/CAF depletion  
 Because phosphorylation of S15 and acetylation of K382 was dependent upon the 
presence of P/CAF, we reasoned that disruption of the MDM2-p53 complex or formation 
of an MDM2-p14ARF may require P/CAF as an additional cofactor, and that its 
depletion may preclude efficient phosphorylation of MDM2 or p53. To address whether 
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P/CAF affects MDM2-p14ARF or MDM2-p53 complexes, we transfected p53-null 
H1299 cells, which maintain relatively high levels of p14ARF, with p53 and 
immunoprecipitated MDM2 in cells expressing either a control or P/CAF siRNA. As 
observed in previous experiments, P/CAF depletion had no impact on steady-state levels 
of MDM2, p53, or p14ARF, and MDM2-p14ARF and MDM2-p53 complexes appeared 
unaffected by P/CAF knockdown (Figure 3.3). 
 
Analysis of MDM2 Localization in H1299 cells after P/CAF depletion 
 Much attention has been given to the observation that p14ARF appears to direct 
MDM2 to the nucleolus upon its expression (Weber et al., 1999), although the 
physiologic importance of this event is still contentious, and does not appear to constitute 
a strict requirement for p53 stabilization by p14ARF (Llanos et al., 2001).  Because 
MDM2-ARF complex formation was unaffected by P/CAF depletion, we reasoned that 
the complex may fail to be properly localized to nucleoli after p14ARF expression, 
potentially allowing high levels of MDM2 to remain in the nucleoplasm and antagonize 
p53 activity. To address this possibility, we again utilized p53-transfected H1299 cells, as 
the steady-state levels of the proteins in question were previously observed to remain 
unchanged after P/CAF knockdown, allowing simpler interpretation of 
immunofluorescence experiments. Unfortunately, significant background staining for 
P/CAF was evident and, furthermore, we were unable to determine whether the intensity 
of MDM2 nucleolar staining was reduced upon depletion of P/CAF (Figure 3.4). 
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Figure 3.1: p300, CBP, and P/CAF are all necessary for acetylation of p53 K382 in 
response to p14ARF. 
 
Plating, transfection, lysis, and separation by SDS-PAGE of U2OS and RPE cells was 
performed as described. 10ug each lysate was run in an initial experiment to determine 
total p53 levels (data not shown). Following densitometric analysis, lysates were 
separated again by SDS-PAGE with the purpose of loading equal amounts of total p53 to 
allow easier analysis of the fraction of K382-acetylated to total p53. Antibody specific to 
K382-acetylated p53 (#06-758) was purchased from Upstate.  
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Figure 3.1: p300, CBP, and P/CAF are all necessary for acetylation of p53 K382 in 
response to p14ARF 
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Figure 3.2: p53 serine-15 phosphorylation is induced by p14ARF and dependent on 
p300, CBP, and P/CAF. 
 
U2OS and RPE1 cells were plated, transfected, lysed and separated by SDS-PAGE as 
described above. 20ug total protein was run from each sample, due to an inability to load 
enough lysate to equalize total p53 levels in this experiment. Antibody specific to S15-
phosphorylated p53 (#9284) was purchased from Cell Signaling Technology.  
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Figure 3.2: p53 serine-15 phosphorylation induced by p14ARF in U2OS and RPE1 cells 
is dependent on p300, CBP, and P/CAF 
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Figure 3.3: The MDM2 Interaction with p14ARF or p53 is Unaffected by P/CAF 
Depletion. 
H1299 cells were plated at a density of 1.5x10^6 cells per 10cm dish, transfected with 
10nM control or P/CAF siRNA using Lipofectamine 2000, and transfected the next day 
again with 1ug pCMV-p53 or pCMV using Lipofectamine 2000 (Invitrogen). Cells were 
harvested 24 hours post-transfection with 1mL NP-40 buffer (1% NP-40, 150mM NaCl, 
50mM Tris pH 8.0, 1mM PMSF, 100uM DTT) and lysed for 30 minutes on ice. Lysates 
were centrifuged at 12,000 rpm at 4°C, and 400uL each lysate was immunoprecipitated 
with 1ug rabbit IgG or MDM2 N-20 antibody (Santa Cruz) overnight. 20uL PBS-washed 
Protein A-agarose beads were added to each reaction and rotated for 1 hour. Reactions 
were then washed three times with 1mL NP-40 buffer and analyzed by SDS-PAGE. 20uL 
lysate was run on the same gel as a 5% input. 
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Figure 3.3: The MDM2 Interaction with p14ARF or p53 is Unaffected by P/CAF 
Depletion  
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Figure 3.4: Analysis of MDM2 Localization in H1299 Cells After P/CAF Depletion. 
H1299 cells were plated on tissue culture dishes with an acid-washed cover slip at a 
density of 1x10^5 cells per 60mm dish. Cells were transfected the next day with 10nM 
control or P/CAF siRNA using Lipofectamine 2000 (Invitrogen), then again the next day 
with 10nM siRNA in combination with 200ng pCMV-p53. Cells were fixed in methanol 
24 hours after transfection and stained with PCAF E-8 antibody (Santa Cruz) and MDM2 
N-20 antibody (Santa Cruz). All imaging settings were set to the same parameters when 
imaging each population of cells. 
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Figure 3.4: Analysis of MDM2 Localization in H1299 Cells After P/CAF Depletion 
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Discussion 
The p14ARF tumor suppressor is vital in transduction of oncogenic signaling to 
p53, which controls the context-dependent outcome of many cellular stresses. Ectopic 
p14ARF expression has been shown to induce acetylation of p53 on various lysines; 
however, the HAT or HATs which mediate acetylation of p53 in response to oncogenic 
stress remain unknown. Here we have demonstrated that p300/CBP-associated factor 
(P/CAF), but not p300 or CBP, is required for p14ARF-dependent stabilization of p53 
and induction of p21 in human cells. 
The Androphy lab recently reported that the human homolog of the transcription 
cofactor hADA3 is required for p14ARF signaling, and that siRNA-mediated loss of 
hADA3 or expression of a dominant negative N-terminal truncation abolishes p53 
acetylation and stabilization in response to p14ARF, preventing p21 activation and cell 
cycle arrest (Sekaric et al., 2007b). Interestingly, hADA3 has been recognized as a 
component of the P/CAF complex (Li et al., 1998). Because loss of hADA3 or P/CAF 
function results in a similar loss of p14ARF signaling, it is likely that the activity of an 
intact P/CAF complex is required to transduce oncogenic signals from p14ARF to p53, 
and may act at the level of acetylation.    
That p53 is acetylated in response to stress stimuli is well established; it was the 
first non-histone protein determined by mass spectrometric analysis to be acetylated on 
various lysines. However, the importance and impact of this modification on p53-
dependent senescence, arrest, or apoptosis has not been well-studied. Most reports to date 
have utilized in vitro acetylation or overexpression assays to demonstrate that p53 is a 
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substrate of of many HATs.  
The role of P/CAF in p53 stability and transcriptional activity is not well 
understood. Mechanistically P/CAF may activate p53 directly by acetylation of p53 
protein or indirectly by modulating activities of other proteins involved in p53 regulation. 
Site-specific antibodies detect a very modest increase in Ac-K320 signal following UV 
irradiation, but the significance of this modification is unknown. Most reports that P/CAF 
affects p53 activity through acetylation utilize in vitro and overexpression studies, and 
detect acetylation using site-specific antibodies which are often unreliable, as they often 
cross-react with other residues or have off-target affinities. Although p53 and P/CAF 
have been reported to interact directly in GST-binding experiments (Liu et al., 1999), our 
attempts to co-immunoprecipitate FLAG-tagged P/CAF with p53 after overexpression in 
H1299 cells were not successful so far (data not shown). Mass spectrometry of in vitro 
acetylated p53 fragments does indicate that lysine-320 is substrate of P/CAF in vitro 
(Sakaguchi et al., 1998); however, the transcriptional activity of a p53 lysine-320 mutant 
is only mildly affected when assayed by a PG13-luciferase reporter. The experiments 
presented here highlight a much more critical role for P/CAF in p53 signaling, as its 
ablation by siRNA abolishes p14ARF signaling upstream of p53 (Figure 2.1)  
P/CAF is known to be involved in MyoD-dependent differentiation through 
regulation of p21 induction (Puri et al., 1997); however, a role for P/CAF upstream of 
p53 stabilization is surprising. A recent report suggests that P/CAF bears E3 ubiquitin 
ligase activity toward MDM2 in vitro and in vivo (Linares et al., 2007), and modulation 
of MDM2 levels and activity presents an attractive model for stress-induced p53 
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stabilization; however in our experiments, both a widely-used monoclonal and polyclonal 
antibody against MDM2 failed to detect a significant change in MDM2 levels after 
P/CAF knockdown (Figure 2.7).  
This does not rule out the possibility that P/CAF exerts other effects on MDM2 
such as relocalization to the nucleolus; however, this function of ARF has been proposed 
to be dispensable for signaling to p53, at least in mice (Llanos et al., 2001). Interestingly, 
however, our data indicate that P/CAF may indeed play a role in the relocalization of 
MDM2 to the nucleolus (Figure 3.4). Many further experiments will be necessary to test 
this intriguing hypothesis. Most importantly, a necessary control that should be included 
in a repeat experiment is depletion of p14ARF by siRNA, which should result in potent 
nucleolar exclusion. 
Interestingly, data from p53-null H1299 cells (Figure 2.6) indicates that P/CAF is 
required for activation of p21 downstream of p53 stabilization. When p53 is expressed in 
H1299 cells p21 is strongly induced, indicating an otherwise intact p53 signaling 
pathway; however, co-expression of P/CAF siRNA with p53 does not culminate in p21 
induction, despite the presence of similar p53 levels. These data suggest that P/CAF is 
not only important for ARF signaling upstream of p53 stabilization, but that P/CAF is 
also required for p21 induction in the presence of high levels of p53. This may reflect a 
requirement for two independent functions of P/CAF; a well-described transcriptional co-
activator function, necessary for initiating p53-dependent transcription at target 
promoters through histone acetylation, and a function in promoting p53 stabilization 
which has yet to be elucidated. 
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A negative role for p300 and CBP in regulation of steady-state p53 levels is 
surprising given that several reports suggest that p300 and CBP serve as coactivators for 
p53-dependent transcription (Lill et al., 1997; Scolnick et al., 1997). Interestingly, recent 
evidence suggests that p300 bears E3 ubiquitin-ligase activity in vitro toward p53 
(Grossman et al., 2003a). In agreement with this study, our in vivo data demonstrate that 
loss of endogenous p300 or CBP result in an increase of steady-state p53 in the absence 
of any specific stress stimulus. A coactivator role for p300 in activation of p53-dependent 
transcription is clear, but how the newly described ubiquitin ligase activity of p300 
impacts p53 signaling has not been explored. It is possible that coupled coactivation and 
ubiquitin ligase activities play vital roles in transcription; recent studies suggest that 
transcription factors may be ‘cleared’ off target promoters through the ubiquitin-
proteasome system (Muratani and Tansey, 2003). We cannot rule out the possibility that 
loss of p300/CBP may increase p53 levels indirectly by induction of oxidative stress, 
which could result in activation of p53 signaling. As ATM was reported to be required for 
the p14ARF response (Li et al., 2004), it is possible that P/CAF is required for ATM 
signaling to p53 upon p14ARF expression. 
That knockdown of p300/CBP induces accumulation of p53 is in agreement with 
several recent studies (Grossman et al., 2003b; Linares et al., 2007; Shi et al., 2009b). 
These data suggest a negative role of p300/CBP in p53 regulation. Paradoxically, the data 
also suggest that p300 and CBP are required for K382 acetylation (Figure 3.1), 
supporting a dual role for p300/CBP in p53 regulation. Moreover, p53 accumulation 
without acetylation of  K382 is a surprising and unexpected observation that suggests an 
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alternative mechanism of p53 stabilization that does not involve K382 acetylation – 
perhaps primarily achieved through inhibition of p53 ubiquitination.  
One intriguing possibility is that the presence or absence of P/CAF in the 
p300/CBP HAT complex constitutes a ‘switch’ in activity between a degrading or 
activating complex. Most endogenous MDM2 has been shown to be in complex with 
p300, and these complexes are known to play a role in p53 degradation (Grossman et al., 
1998). Furthermore, adenoviral E1A displaces P/CAF from the p300/CBP complex and 
stabilizes p53 in a p300/CBP-dependent manner, suggesting that the presence of P/CAF 
in the complex could serve as a bias toward activation and against degradation of p53; 
furthermore, given that HPV E6 was recently shown to inhibit p300-mediated p53 
acetylation in an in vitro system containing reconstituted chromatin templates (Thomas 
and Chiang, 2005) , it will be interesting to further investigate the role of viral oncogenes 
on various coactivator complexes known to play a vital role in tumor suppression. 
 
Materials and Methods 
Reagents 
pCI-PCAF, pcDNA3-p14ARF and pcDNA3 were used for DNA transfections and 
have been previously described (Llanos et al., 2001). 10uM Trichostatin A (TSA) was 
added to lysates to be blotted with acetylation-specific antibodies. pCI-PCAF lacking the 
HAT domain (Δ608-629) was created by site-directed PCR mutagenesis and sequenced to 
rule out the possibility of secondary mutations. 
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Cell Lines and Antibodies 
RPE1 cells and U2OS cells were grown under conditions suggested by ATCC. 
Antibodies used to detect endogenous protein levels were as follows: PCAF was detected 
with mouse monoclonal antibody E8 (Santa Cruz), p300 with rabbit polyclonal N-15 
(Santa Cruz), CBP with rabbit polyclonal E14 (Santa Cruz) MDM2 with rabbit 
polyclonal antibody N20 (Santa Cruz), p53 with mouse monoclonal DO-1 or rabbit 
polyclonal FL-393 (Santa Cruz), p21 with mouse monoclonal 6B6 (Upstate), actin with 
rabbit polyclonal (Sigma), and Ac-K320 and Ac-K382 p53 with rabbit polyclonal 
antibodies (Upstate). 
 
Transfections 
RPE1 or U2OS cells were plated at a density of 1x10^6 cells/10cm dish 24 hours prior to 
transfection. Cells were then transfected with 10nM siRNA targeting p300, CBP, PCAF, 
or a negative control siRNA (Ambion) using Lipofectamine 2000 (Invitrogen). After 24 
hours, cells were transfected again with 10nM siRNA, 1ug pcDNA3-p14ARF or 
pcDNA3, and 4ug salmon-sperm DNA. Cells were harvested 48 hours after the second 
transfection, lysed using 300uL SDS buffer (2% SDS, 50mM Tris pH 6.8), boiled for 5 
minutes and stored at -80C. Protein concentrations were determined using a BSA 
standard curve, and proteins were separated by SDS-PAGE and blotted using antibodies 
described above. 
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Flow cytometry and PI staining 
Cells were harvested 48 hours after second transfection by scraping and fixed in 
75% EtOH for at least 24 hours. Cells were stained with 50ug/mL propidium iodide in 
PBS and treated with 100uL of 100mg/mL RNAse prior to flow cytometric analysis by 
the UMMS FACS core facility. Data was analyzed using FlowJo (Tree Star, Inc.) 
 
Immunoprecipitation 
H1299 cells were plated at a density of 1.5x10^6 cells per 10cm dish, transfected 
with 10nM control or P/CAF siRNA using Lipofectamine 2000, and transfected the next 
day again with 1ug pCMV-p53 or pCMV using Lipofectamine 2000 (Invitrogen). Cells 
were harvested 24 hours post-transfection with 1mL NP-40 buffer (1% NP-40, 150mM 
NaCl, 50mM Tris pH 8.0, 1mM PMSF, 100uM DTT) and lysed for 30 minutes on ice. 
Lysates were centrifuged at 12,000 rpm at 4°C, and 400uL each lysate was 
immunoprecipitated with 1ug rabbit IgG or MDM2 N-20 antibody (Santa Cruz) 
overnight. 20uL PBS-washed Protein A-agarose beads were added to each reaction and 
rotated for 1 hour. Reactions were then washed three times with 1mL NP-40 buffer and 
analyzed by SDS-PAGE. 20uL lysate was run on the same gel as a 5% input. 
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Chapter IV 
Conclusions and Future Directions 
 
 The nature of biological research necessitates the continuous refinement of 
models and hypotheses as new information is brought to light, and the field of p53 
transcription is no exception. Beginning, as responsible scientific inquiry does, with the 
simplest explanation which fits the existing data, the model of p53 transcriptional 
activation has ballooned into a strikingly complex one, whereby the cellular fate directed 
by p53 relies on countless levels of transcriptional regulation few would have ever 
suspected. Beyond the value of p53 as a model for the broad study of transcriptional 
processes, a complete understanding of a transcriptional network so central to human 
disease will someday allow us to manipulate these networks for eventual therapeutic 
benefit. In addition, an equally comprehensive understanding of the upstream signals 
which govern p53 activation will complement this knowledge, potentially allowing the 
restoration of these stress sensors in cells with defects in the p53 network through a 
number of means. The work presented in this thesis defines the histone acetyltransferase 
P/CAF as playing vital and independent roles in both p53 transactivation of p21 and 
transduction of oncogenic signaling from p14ARF to p53, and challenges its putative role 
in p53 activity as being confined to acetylation of p53 K320. 
 
The Role of P/CAF in Stress-induced p21 Transcription 
An siRNA-based approach was undertaken to examine the role of p300, CBP, and 
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P/CAF in p53 stabilization and p21 induction in response to p14ARF transfection in 
U2OS cells. It was noted that p300 and CBP depletion resulted in spontaneous elevation 
of p53 and p21 levels, consistent with a negative role for p300 and CBP in p53 stability 
and activity under basal conditions (Shi et al., 2009a). P/CAF, in contrast, prevented p53 
stabilization and p21 induction after p14ARF transfection (Figure 2.1). 
Reasoning that a defect in p53 acetylation in the absence of P/CAF might explain 
the failure in p53 stabilization and p21 induction, we turned to p53-null H1299 cells with 
which we could study various p53 mutants and their p21 response. Surprisingly, p21 
expression induced by transfected, wild-type p53 was dependent on P/CAF in H1299 
cells, despite p53 being present at similar levels in all conditions (Figure 2.3A). This 
result clearly indicates that P/CAF plays a role in p21 expression independently of 
regulating p53 levels. Reasoning that P/CAF was necessary for p21 expression through 
acetylation of p53 K320, we transfected a p53 K319-321R mutant into H1299 cells, 
expecting it to be deficient in inducing p21 expression; surprisingly, the K319-321R 
mutant was fully competent for p21 induction, which again was fully dependent upon the 
presence of P/CAF (Figure 2.6). This result clearly indicates that P/CAF plays a critical 
role in p53-dependent p21 expression independent of K320 acetylation. 
Subsequent experiments in U2OS cells indicate that P/CAF is required for p21 
induction in response to a variety of p53-activating stresses – UV irradiation, doxorubicin 
, nutlin-3, and p14ARF expression; interestingly, P/CAF knockdown did not affect stress-
induced p53 accumulation in any case except p14ARF expression (Figure 2.3), 
suggesting a role for P/CAF in p53 stabilization specific to p14ARF, which will be 
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discussed in more detail below. 
The work presented in Chapter 2 raises a number of questions which will be 
addressed by future experiments. Of immediate interest is whether the role for P/CAF in 
p53-activated transcription is limited to p21, or a broader subset of p53-responsive genes. 
One assumption challenged by recent work attempting to unravel the complexity of the 
p53 transcriptional response is that p53-responsive genes can simply be categorized by 
their roles in apoptosis or cell-cycle arrest, or by a simple division based on promoter 
affinity. The recent and thorough analyses of the PUMA and p21 promoters by several 
labs (Donner et al., 2007; Gomes and Espinosa, 2010b; Morachis et al., 2010) suggests 
that the native chromatin architecture inherent to specific promoters greatly impacts 
activation and expression kinetics. These recent observations preclude the prediction of 
which additional p53 targets might depend on P/CAF, but it is possible that P/CAF might 
be recruited to p53-responsive genes located in tightly or heavily chromatinized regions 
of the genome where H3K14 acetylation is required to allow de-compaction of chromatin 
to facilitate transcriptional initiation and elongation. Another possibility is that P/CAF 
might be recruited to those target genes which require numerous rounds of transcription 
to produce a sustained elevated expression level, such as p21. Regardless of whether such 
predictions may serve to be informative, a thorough analysis of known p53 target genes 
by chIP analysis of P/CAF is a necessary next step to more accurately determine the 
global role of P/CAF in p53-dependent transcription. 
Another major question arising from this work is which p53 HAT or HATs 
mediate K320 acetylation. Results from previous experiments in the Androphy lab 
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(unpublished) using p53-transfected H1299 cells indicate that P/CAF knockdown 
actually increases basal levels of acetylated K320 and decreases levels of acetylated 
K382, while p300 overexpression in H1299 cells strongly stimulates K320 acetylation. It 
will be important to validate published results in this system by showing that, as 
published, P/CAF overexpression stimulates K320 acetylation. Several simple 
experiments could address the apparent contradiction that both P/CAF overexpression 
and ablation stimulate K320 acetylation. One possibility is that elevated GCN5 in 
P/CAF-depleted cells could promote K320 acetylation. This possibility is easily 
addressed through a simultaneous knockdown of P/CAF and GCN5. Another possibility 
is that P/CAF and/or GCN5 serve as adaptors for K320 acetylation by p300 or CBP. 
Several experiments could address this – first, a P/CAF or GCN5 HAT mutant should still 
stimulate K320 acetylation, assuming such a mutant could still serve as an adaptor for the 
relevant HAT. Another informative experiment would be overexpression of p300 or CBP 
in a P/CAF and GCN5-depleted population of cells. If p300 or CBP are K320 
acetyltransferases dependent upon P/CAF or GCN5, they should stimulate acetylation of 
K320 only in the presence GCN5 or P/CAF. These experiments could address the 
confounding issue of which, if any, of these HATs are responsible for K320 acetylation. 
Identification of the HAT(s) mediating K320 acetylation will yield valuable insight into 
the regulation of cell fate by HATs, as acetylation of K320 seems to be an important 
factor in cell-fate decision by p53. 
Intriguingly, our work indicates that p53 is pre-loaded at the p21 promoter, yet 
histone acetylation at the promoter increases in response to stress, raising the question of 
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how acetylation is stimulated. That the interruption of the p53-MDM2 complex alone by 
nutlin-3 is sufficient to promote p21 expression and histone acetylation at the promoter 
suggests that MDM2 may play a role in this process, perhaps through association with the 
p21 promoter in non-stress conditions. MDM2 is well-known to interact with HDAC1 to 
antagonize p53 function through deacetylation (Ito et al., 2002; Ito et al., 2001), raising a 
few possibilities: that MDM2-mediated deacetylation of p53 at the p21 promoter inhibits 
its interaction with HATs, or that a relevant function of the MDM2-HDAC1 may, in fact, 
be deacetylation of histones at p53-responsive promoters. Detection of P/CAF at the p21 
promoter or in complex with p53 has so far been problematic, despite reports describing 
both promoter and direct interactions (Dell'orso et al., 2011; Knights et al., 2006). A 
thorough chIP analysis of the dynamics of p53 complexes present at the p21 promoter 
before and after stress should begin to address how histone acetylation at the p21 
promoter is regulated. 
Finally, the results presented herein further support a critical role for histone 
acetylation at the p21 promoter in p21 transcriptional activation. Work from the Espinosa 
lab indicate that levels of H3K9 and total H4 acetylation at the p21 promoter increase 
under stress conditions, even those that do not culminate in p21 transcription (Donner et 
al., 2007), suggesting that subsequent regulatory events define the final outcome. Our 
work complements this view, suggesting that, while histone acetylation at the p21 
promoter is not sufficient to direct transcriptional activation, it may be necessary for 
additional regulated downstream which promote elongation of the RNAP II complex. 
While histone acetylation at other p53 target promoters is likely important for their 
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activation, the factors necessary for transcriptional activation may differ between p53 
target promoters. 
 
The Role of P/CAF in the p14ARF-p53 Oncogenic Stress Response 
 The second body of work in this dissertation characterizes the role of previously 
identified p53 HATs in p14ARF-p53 signaling. A better understanding of how p14ARF 
transduces oncogenic signals to direct cell-cycle arrest or senescence will be critical to 
the identification of therapeutically relevant targets. Furthermore, p14ARF signaling has 
found renewed importance with the recent observation that p14ARF-p53 signaling is a 
barrier to the generation of induced pluripotent stem (iPS) cells (Banito et al., 2009; Hong 
et al., 2009; Li et al., 2009). Identification and characterization of factors regulating 
p14ARF signaling might potentially be useful in the short-term inactivation of this 
pathway to facilitate reprogramming. 
This project began with the same siRNA-based approach as described in the 
previous section. In this experimental setting, p300 and CBP played negative roles in p53 
stability and activity, as their abrogation resulted in spontaneous stabilization and 
activation of p53, as evidenced by increased basal p21 levels. The results were virtually 
indistinguishable in the presence of p14ARF. Because p300 and CBP are known to 
acetylate p53 and function as coactivators, it will be interesting to determine whether 
simultaneous knockdown of p300 and CBP would still result in spontaneous p21 
induction. Presumably, p53 should still exhibit the increased half-life in this setting that is 
seen in individual p300 or CBP knockdowns; however, if p300 or CBP-mediated 
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acetylation of p53 is necessary for activation of p21, as a recent report suggests (Tang et 
al., 2008), one might expect that stable p53 in this context may be unable to transactivate 
the p53 promoter. 
In contrast, P/CAF knockdown had no significant effect on basal levels of p53 or 
p21 but, upon expression of p14ARF, completely prevented p53 stabilization and p21 
induction, suggesting a critical role for P/CAF in p14ARF signaling (Figure 2.1). To 
ensure that these observations were not simply artifacts of the experimental system, the 
experiments were repeated in non-transformed RPE1 cells, which had been immortalized 
by the introduction of hTERT. Results from RPE1 cells closely matched those obtained 
from U2OS cells (Figure 2.1A-B), indicating that P/CAF plays a critical role in p53 
stabilization and activation in response to ARF. Expecting that P/CAF was exerting its 
effects on p53 through acetylation, we examined post-translational modifications of p53 
in response to p14ARF – specifically, S15 phosphorylation and K382 acetylation. 
Strikingly, although p14ARF expression stimulated both modifications, neither was 
detectable upon the depletion of any of the HATs tested (Figure 3.1 and 3.2). This 
suggests that the presence of all three HATs is required for S15 phosphorylation and 
K382 acetylation in response to p14ARF. 
Two distinct possibilities arise from this observation: either that depletion of any 
one HAT makes the total pool of p53 HATs limiting for p53 acetylation, or that these 
HATs function together in concert or sequentially to direct p53 modification in response 
to p14ARF. These possibilities could be addressed by rescuing individual knockdowns by 
expression of heterologous HATs. This experiment also indicates that, in the case of p300 
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and CBP, these modifications are dispensable for activation of p21 expression. It will be 
important, however, to determine whether p21 induction by p300 or CBP knockdown is 
p53 dependent, and whether it is regulated at the level of transcription or protein stability. 
Although no clear role for p300 and CBP in p14ARF signaling has been 
identified, some tangential evidence links the two – several reports have linked ATM to 
p14ARF function, while others have linked p300 to ATM function. The earliest report 
noted that S15 phosphorylation of p53 and cell-cycle inhibition directed by p14ARF are 
attenuated in cells from Ataxia Telangiectasia patients who harbor mutations in both ATM 
alleles (Li et al., 2004). A later report expands upon this observation, noting that p14ARF 
specifically activates ATM signaling in a p53-independent manner (Eymin et al., 2003). 
p300 activity has been linked to the DNA-damage response through roles in histone 
acetylation (Vempati et al., 2010), and through regulation of stability of NBS1, a factor 
critical to DNA-damage repair processes (Jang et al., 2011{Jang, 2010 #1079). This 
raises the possibility that p300 plays upstream roles in p14ARF-p53 signaling not limited 
to regulation of p53 stability, but involving ARF-directed activation of ATM signaling. It 
will be important to note whether ATM-signaling in this context does, in fact, impact p53 
activation by ARF, and whether p300 regulates this process. The use of p300/CBP 
mutants deficient in E3 ligase or HAT activities to rescue knockdowns will be helpful in 
addressing these possibilities. 
While it is clear that P/CAF regulates p53 levels and activity in response to 
p14ARF, how these effects are achieved is unclear. A recent report identified P/CAF as an 
E3 ligase for human MDM2 (Linares et al., 2007), an intriguing observation that could 
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potentially explain the role of P/CAF in p14ARF signaling; however, our repeated 
attempts to reproduce these results have so far failed, despite performing the experiments 
in the same cell type and using the same reagents. Specifically, where the authors see a 
marked elevation of MDM2 levels in response to P/CAF knockdown in U2OS cells after 
two hours, we observe no increase in MDM2 levels at this time point (Figure 2.7). The 
reasons for this discrepancy are unclear, but may relate to clonogenic differences between 
populations of the same cell type grown in culture, or may reflect a differential 
environmental stress between the two culture conditions. It is possible that specific 
conditions exist in which depletion of P/CAF would result in elevated MDM2 levels, but 
we have so far been unable to identify such a set of conditions. 
Because ablation of P/CAF does not appear to alter basal levels of factors in the 
p14ARF-p53 response (Figure 2.1, Figure 3.3), we reasoned that P/CAF could be 
exerting its effects through modulation of protein-protein interactions or localization of a 
number of factors. To this end we examined the interaction of MDM2 with both p53 and 
p14ARF in p53-transfected H1299 cells (Figure 3.3). p14ARF and p53 co-
immunoprecipitated efficiently with MDM2 in both the presence or absence of P/CAF, 
indicating that P/CAF is dispensable for both MDM2-p53 and MDM2-p14ARF 
interaction. We also examined the localization of MDM2 and p14ARF in this 
experimental setting, reasoning that perhaps P/CAF was necessary for p14ARF-directed 
nucleolar relocalization of MDM2. While significant background fluorescence of P/CAF 
staining was evident, MDM2 appeared to exhibit a greater degree of nucleolar exclusion 
in the absence of P/CAF (Figure 3.4).  
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This raises the intriguing possibility that a nucleoplasmic pool of active MDM2 
exists which, upon p14ARF expression, is normally directed to nucleoli. In the absence of 
P/CAF, p14ARF may fail to relocalize MDM2 to nucleoli, leaving an active pool of 
MDM2 to antagonize p53 function even in the presence of ARF. Precisely how this 
would be achieved is not immediately clear – as mentioned above, P/CAF does not 
appear to impact the MDM2-p14ARF interaction; however, a more careful analysis 
should be performed to ensure that an MDM2-p14ARF complex is not reformed after 
lysis. 
It is possible that P/CAF alters other, as yet undefined components of the MDM2-
p14ARF complex. Gel filtration of the purified complex could aid in identification of 
new components of the complex, or at least provide qualitative data regarding the nature 
of the complex in the presence or absence of P/CAF. It is also possible that the novel E3 
ligase activity of P/CAF could play a role in the regulatory ubiquitination of the p14ARF-
MDM2 complex and facilitate its nucleolar translocation. While this is a preliminary 
result with which care should be taken to avoid over-interpretation, the possibility that 
P/CAF regulates MDM2 or p14ARF localization certainly warrants further attention. 
Attempts to rescue the defect in p53 stabilization with P/CAF mutants could also provide 
insight into which, if any, biochemical activities of P/CAF are necessary to promote 
ARF-induced p53 stabilization. 
 
P/CAF: A Role in Tumor Suppression? 
 Dual critical roles for a coactivator in such a vital tumor suppressor pathway 
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might suggest that P/CAF itself is inactivated in some subset of tumors. The designation 
of a factor as an oncogene or tumor suppressor is, in many cases, straightforward; 
however, in the case of HATs, with a myriad of substrates often encompassing both 
oncogenes and tumor suppressors, the role of these factors in tumor progression is often 
highly context dependent. The impact of loss of activity of a HAT could presumably 
depend on the initiating lesion(s), the tissue affected, and the precise balance of 
oncogenes and tumor suppressors during the time at which a HAT becomes inactivated, 
whether through epigenetic means or loss of heterozygosity. It is reasonable to propose 
that if several driving oncogenes were dependent upon a HAT, its loss of activity might 
result in the elimination of the cell from the replicative pool; whereas, if wild-type p53 
were present, loss of a critical HAT might phenocopy p53 loss and allow the cell to 
continue the progression toward a transformed state. If this in indeed the case, HATs in 
general should show a lower rate of mutation and exhibit a more limited spectrum of loss 
in human malignancies. 
 Evidence to date seems to support that loss of activity of the HATs discussed in 
this dissertation – p300, CBP, P/CAF, Tip60 – do, in specific cases, function as tumor 
suppressors and possibly (in rare cases) acquire oncogenic functions. Tip60, for example, 
commonly undergoes loss of a single allele in many lymphomas, mammary carcinomas, 
and head-and-neck carcinomas, defining Tip60 as a non-classical haploinsufficient tumor 
suppressor (Gorrini et al., 2007). CBP mutations cause the developmental disorder 
Rubenstein-Taybi syndrome, which is characterized by a high rate (about 5%) of neural 
crest tumors (Miller and Rubinstein, 1995). Many reports of spontaneous mutation of 
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p300 and CBP in human solid tumors have also been described. p300 is subject to 
inactivating mutations with LOH in gastric and colorectal tumors (Muraoka et al., 1996), 
and CBP in ovarian tumors (Ward et al., 2005). In most tumors screened, however, the 
rate of inactivating mutation with LOH was between 1-5% for p300 (Muraoka et al., 
1996) (Gayther et al., 2000; Ozdag et al., 2002), and even more rare for CBP (Ozdag et 
al., 2002). Importantly, no significant inverse correlation appears to exist between p53 
and CBP/p300 status, suggesting that the role of CBP/p300 inactivation in tumors is not 
confined to (and may be entirely independent from) those harboring wild-type p53. This 
suggests that, under certain conditions, p300 or CBP inactivation can contribute to 
tumorigenesis. 
In leukemias and lymphomas, the role of p300 and CBP appear to be more 
complex, as they are, in rare cases, subjects of chromosomal rearrangements resulting in 
oncogenic fusion proteins (Borrow et al., 1996; Champagne et al., 2001; Giles et al., 
1997). Despite this oncogenic gain-of-function, evidence from mice still suggest that loss 
of activity of p300 or CBP contribute to the onset of  hematological malignancies, as 
blastocysts injected with p300 or CBP-null ES cells developed tumors (Rebel et al., 
2002). Importantly, however, these experiments do not address a post-natal role for p300 
and CBP in tumor suppression. It will be interesting to track future research regarding the 
mechanism through which p300 and CBP loss-of-function contribute to tumorigenesis. 
 Evidence for a role of P/CAF in tumor suppression has been more elusive. 
P/CAF-null mice develop normally and are not tumor-prone; however, it is important to 
note that GCN5 is heavily overexpressed in P/CAF-null mice, and likely functionally 
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compensates for P/CAF loss (Yamauchi et al., 2000). Furthermore, several early analyses 
failed to identify inactivating mutations of P/CAF at any significant rate in the tumors 
screened (Muraoka et al., 1996; Nishimori et al., 2000). Two recent reports, however, 
indicate that P/CAF inactivation contributes to tumorigenesis. A very recent report from 
the Avantaggiati lab (Perez et al., 2010) notes that P/CAF expression levels in a panel of 
colon, lung, head-and-neck, and bladder cancers are all significantly lower than matched 
non-tumor tissue. In another study, P/CAF activity appears to be lost through mutation or 
downregulation in a striking 60% of 80 esophageal squamous cell carcinomas screened. 
Reintroduction of P/CAF into cell lines established from several of these primary tumors 
potently inhibited tumorigenicity through reestablishment of a G1/S checkpoint 
associated with upregulation of, among other cell-cycle regulators, p21(Zhu et al., 2009). 
This raises the possibility that P/CAF does, in certain cases, function as a tumor 
suppressor through modulation of p53 activity by histone acetylation of target promoters. 
Because P/CAF does not appear to behave like a classical tumor suppressor, and is 
seemingly downregulated primarily by epigenetic means, a more thorough examination 
of P/CAF levels in various tumors may uncover a broader role for its involvement in 
tumor suppression. 
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Appendix I 
The Transcriptional Adaptor hAda3 Interacts With, But  
Is Not Degraded By High-risk HPV E6 
 
 The hAda3 transcriptional adaptor, a component of the P/CAF HAT complex, has 
been identified as a necessary cofactor in p53 acetylation (Nag et al., 2007; Sekaric et al., 
2007b)and has been identified as a target of high-risk E6-mediated degradation (Kumar et 
al., 2002). Degradation of hAda3 by E6 has been proposed to attenuate p53 activity in a 
manner independent from E6-mediated p53 degradation, and correlates well with the 
efficient immortalization of human mammary epithelial cells (MECs) (Shamanin et al., 
2008), suggesting that degradation of hAda3 by E6 may represent an additional 
oncogenic function of high-risk E6 (of note, low-risk E6 is unable to promote degradation 
of hAda3). 
 The works cited above utilized expression of a FLAG-tagged hAda3 construct to 
demonstrate degradation by E6, due to the lack of antibodies recognizing native hAda3 at 
the time during which these experiments were performed. Generation of a polyclonal 
antibody in the Androphy lab generated by immunization with an N-terminal hAda3 
peptide allowed us to study the impact of E6 on endogenous hAda3. We began by 
comparing the half-lives of untagged or FLAG-tagged hAda3 in H1299 cells expressing 
HPV 16E6 or a vector control by cycloheximide analysis. In agreement with recent 
reports, we observed a reduction in FLAG-hAda3 half-life in the presence of 16E6 
(Figure A1.1A). Strikingly, however, we noted that the half-life of untagged hAda3 was 
112 
 
unaffected by 16E6 expression. Half-lives and steady-state expression levels of FLAG-
tagged or untagged hAda3 were similar (Figure A1.1B). 
 Based on these results, we reasoned that native hAda3 may indeed interact with 
16E6, and that the addition of FLAG tag may provide a lysine which could be targeted by 
the E6/E6AP complex. Alternatively, we thought it possible that the FLAG tag could 
induce a conformational change in hAda3 or itself provide an interaction site for 16E6. 
To address these possibilities, we performed co-immunoprecipitations of endogenous 
hAda3 in H1299 cells expressing 16E6 or a vector control. We noted a weak, but clean 
interaction between hAda3 and 16E6 (Figure A1.2), confirming that 16E6 and hAda3 do 
form a complex in cells. 
 That 16E6 does, in fact, not target hAda3 for degradation calls into question the 
physiologic role of such an interaction. Many possibilities exist – high-risk E6 could 
serve to inactivate several HAT complexes which are known to be limiting, through 
interaction with hAda3, thereby preventing coactivation of p53 or histone acetylation on 
p53-responsive promoters. Alternatively, it is possible that high-risk E6 itself utilizes the 
activity of HAT complexes to promote activation of factors such as c-myc or hTERT 
which contribute to E6-induced immortalization and transformation. A thorough analysis 
of the interaction of HAT complexes with their known transcription factors in the 
presence or absence of high-risk E6 will serve to address these questions. 
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Figure A1.1: hAda3 is not a target of 16E6-mediated degradation. 
 
 H1299 cells were plated at 5x10^5 cells per 60mm plate, and transfected the next 
day with 1ug hAda3 or FLAG-hAda3 (pCDNA3 vector backbone) and 1ug LXSN-16E6 
or LXSN. 24 hours after transfection, cells were treated for the indicated durations with 
50ug/mL cycloheximide (CHX). Cells were immediately lysed after CHX treatment in 
SDS buffer (2% SDS, 50mM Tris pH 6.8) A) 10ug lysates from each CHX treatment 
condition were separated by SDS-PAGE and blotted with the indicated antibodies (M5 
anti-FLAG from Sigma-Aldrich, rabbit hAda3 antibody was generated and validated by 
the Androphy lab) B) 10ug of lysates from untreated samples (t=0) were separated by 
SDS-PAGE and blotted with the indicated antibodies (16E6 antibody was a generous gift 
from Arbor Vita Co.) to indicate steady-state levels of relevant factors. 
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Figure A1.1: hAda3 is not a target of 16E6-mediated degradation. 
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Figure A1.2: HPV 16E6 interacts with endogenous hAda3 in H1299 cells. 
 
 H1299 cells were plated at a density of 1.5x10^6 cells / 100mM dish and 
transfected as described in Figure A1.1. 24 hours after transfection, cells were lysed in 
500uL IP-lysis buffer (50mM Tris pH 8.0, 100mM NaCl, 20mM NaF, 10mM KH2PO4, 
1% Triton X-100, 2mM DTT, 10% glycerol, 1mM PMSF, 1x protease inhibitor cocktail 
(Roche)) for 30 minutes on ice. Immunoprecipitations were performed overnight in a 
total volume of 400uL using 200uL of the relevant lysate and final binding conditions of 
100mM Tris pH 8.0, 100mM NaCl, 10mM NaF, 5mM KH2PO4, 0.5% Triton X-100, 
2mM DTT, 5% glycerol, 1mM PMSF, and 1x protease inhibitor cocktail (Roche). The 
next day, 20uL PBS-washed protein A-agarose beads were added to each reaction and 
bound for an additional 2 hours. Reactions were washed 3 times each with 1mL was 
buffer (100mM Tris pH 8.0, 100mM NaCl, 0.5% NP-40, 1mM PMSF). Samples were 
eluted using 2x Laemmli buffer, boiled for 10 minutes, and separated by SDS-PAGE for 
analysis. Antibodies used for detection by western blot are described in Figure A1.1 
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Figure A1.2: HPV 16E6 interacts with endogenous hAda3 in H1299 cells. 
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